Podcasts about nih

Sean bienvenidos a un nuevo Spaces en directo desde Twitter. Esta será una entradilla corta para hablar sobre los orígenes del poder de la familia Kennedy, para ello voy a utilizar un artículo de la web vigilant citizen,ciudadano vigilante, una especie de técnico preocupado pero de USA. Dice así: “Los Kennedy fueron considerados, en su momento, la Familia Real de Estados Unidos: una poderosa dinastía que además era querida y admirada por el público. Sin embargo, la asombrosa "Maldición Kennedy" impactó profundamente a la familia, ya que numerosos miembros perdieron la vida a temprana edad y en extrañas circunstancias. Esta serie de artículos revelará datos menos conocidos sobre los Kennedy y explicará cómo el destino de la familia se relaciona con el gobierno en la sombra que gobierna Estados Unidos. Joseph Patrick Kennedy Sr. fue quien orquestó el ascenso de la familia al poder. Fue una figura destacada del Partido Demócrata y de la comunidad católica irlandesa de Estados Unidos. También fue un exitoso hombre de negocios, pues amasó una fortuna comprando y fusionando varios estudios cinematográficos de Hollywood e importando y distribuyendo bebidas alcohólicas en Estados Unidos después de la Ley Seca. Durante su carrera política, Kennedy se convirtió en un asesor cercano del presidente Franklin D. Roosevelt y fue nombrado presidente inaugural de la Comisión de Bolsa y Valores de Estados Unidos (SEC). En 1938, fue nombrado embajador de Estados Unidos en el Reino Unido, un prestigioso cargo donde estableció vínculos con la nobleza británica y presenció los inicios de la Segunda Guerra Mundial. Trató con personas pertenecientes a los "linajes Illuminati" (según la definición de Fritz Springmeier), como los Rothschild, los Astor y los Sassoon. Mantuvo una estrecha relación con el magnate periodístico y figura destacada de los Illuminati, William Randolph Hearst, quien posteriormente contribuyó al despegue de la carrera de JFK. Durante la carrera política de Kennedy Sr., asesoró a Roosevelt, masón de grado 33 y primer Gran Maestro Honorario de la Orden de DeMolay. Roosevelt, quien también fue asesorado por los notables ocultistas Manly P. Hall y Nicholas Roerich, ordenó la colocación del Sello de los Estados Unidos (el símbolo Illuminati de la pirámide con el ojo que todo lo ve) en el billete de dólar. Joe Kennedy Sr. también formó parte de varias órdenes de élite, como los Caballeros de Malta y la Sociedad de Peregrinos, un grupo altamente secreto que incluía entre sus miembros a los Rockefeller, los Vanderbilt, JP Morgan, miembros de la realeza británica, varios líderes de la Sociedad Skull and Bones, masones, Caballeros Templarios y presidentes de la Reserva Federal, así como ejecutivos de importantes empresas y medios de comunicación. De hecho, la Sociedad de Peregrinos es probablemente el grupo de élite más influyente que existe. En 1944, Kathleen, hija de Joe Kennedy, se casó con William Cavendish, duque de Devonshire (un cargo muy prestigioso dentro de la nobleza británica). El duque de Devonshire era Gran Maestro de la Gran Logia Unida de Inglaterra, el órgano rector de la mayoría de los masones en Inglaterra, Gales, Estados Unidos y la Commonwealth. Tras el fallecimiento prematuro de su hija, Joseph Kennedy declaró: Si Kathleen y su esposo vivieran, yo sería el padre de la duquesa de Devonshire (primera dama de compañía de la reina) y el suegro del líder de todos los masones del mundo. Por lo tanto, Joseph Kennedy estaba muy bien conectado con la élite oculta y los linajes Illuminati de Estados Unidos y Gran Bretaña. Si bien albergaba la esperanza de convertirse en candidato presidencial, su oportunidad se cerró cuando, ante la amenaza de una invasión nazi, declaró que «la democracia en Gran Bretaña ha terminado», añadiendo que «la batalla por Gran Bretaña no se trata de democracia, eso son puras tonterías». A puerta cerrada, Kennedy también fue descubierto simpatizando con Hitler y el movimiento nazi. También se le citó profiriendo diversas declaraciones antisemitas en conversaciones con los Astor. Consciente de que la indignación que causaba le impediría llegar a la presidencia, Kennedy padre actuó entre bastidores y se concentró en «colocar» a sus hijos en puestos de poder. Tenía la riqueza y, aún más importante, los contactos con la élite necesarios para que sus planes se hicieran realidad.” Robert F. Kennedy Jr., nacido el 17 de enero de 1954 en Washington D.C., es un abogado, activista ambiental y figura pública estadounidense, y su reciente papel como Secretario de Salud y Servicios Humanos (HHS) desde febrero de 2025, lo que ha generado controversia, especialmente por sus políticas sobre vacunas. Conocido por ser parte de la influyente familia Kennedy. Hijo de Robert F. Kennedy, exfiscal general y senador, y sobrino del presidente John F. Kennedy, ha forjado su propio camino, centrándose principalmente en el activismo ambiental y, más recientemente, en posturas controvertidas sobre la salud pública. Como presidente de la Waterkeeper Alliance (Alianza para la protección del agua), una organización dedicada a la protección de los recursos hídricos, Kennedy ha liderado esfuerzos para combatir la contaminación y promover esa palabreja tan manida por los de la agenda 2030, la sostenibilidad, ganándose reconocimiento por su trabajo en defensa del medio ambiente. Su trayectoria como abogado ambientalista incluye casos destacados contra grandes corporaciones por daños ecológicos, aunque si rascamos un poco vemos que la asociación Riverkeeper, la organización fundadora del movimiento fue la que logro la recuperación del rio Hudson por mas de mil millones de dólares. Ambas organizaciones fueron pioneras en reclamar la "restauración" de los ríos, un eufemismo que en realidad significa la destrucción de presas y otras infraestructuras hidráulicas y energéticas. Modelo que se ha replicado en todo el mundo golpeando especialmente a España. Los otros litigios han sido muy mediáticos pero en realidad hablamos de poco dinero y poca afectación para las multinacionales que contaminan el planeta de verdad. Kennedy comenzó su carrera profesional como asistente de distrito en Manhattan y, en la década de 1980, se unió a organizaciones como Riverkeeper y el Consejo de Defensa de Recursos Naturales (NRDC), enfocándose en la protección ambiental. En 1986, se convirtió en profesor adjunto de derecho ambiental en la Universidad Pace y, en 1987, fundó la Clínica de Litigios Ambientales de Pace. En 1999, fundó Waterkeeper Alliance, de la cual fue presidente durante 21 años, liderando esfuerzos globales para proteger los recursos hídricos. Su trabajo incluyó demandas exitosas contra municipios y corporaciones por violaciones de la Ley del Agua Limpia, consolidándolo como una voz prominente en la defensa del medio ambiente. Recibió reconocimientos como "Héroe del Planeta" de la revista TIME y el Premio Sartisky a la Paz, reflejando su impacto en este ámbito. Nosotros sabemos que Roma no premia a traidores, ergo, el no ha traicionado a Roma. Su carrera inicial se centró en la conservación de ecosistemas y la lucha contra la contaminación, especialmente en el impacto de estas en la salud humana. En 2014, co-fundó Children's Health Defense, una organización dedicada a abordar el aumento de condiciones crónicas infantiles, como el autismo, lo que marcó su transición hacia temas de salud pública. Children’s Health Defense (CHD), fundada por Robert F. Kennedy Jr., mantiene una postura crítica hacia la vacuna triple vírica (MMR, contra sarampión, paperas y rubéola), centrada en cuestionar su seguridad, eficacia y obligatoriedad. Esta afirmación se basa en el estudio de Andrew Wakefield de 1998, que relacionaba la MMR con el autismo. Dicho estudio fue retractado por supuestos fraudes científicos aunque si investigamos veremos que se trata de una argucia legal. A través de su sitio web, redes sociales y documentales como Vaxxed (coproducido por CHD), la organización difunde mensajes que cuestionan la MMR, alegando que los riesgos no se divulgan adecuadamente. Esta organización y sus posturas han sido criticadas por promover teorías conspirativas, como la idea de que la enfermedad de Lyme es un arma biológica, una afirmación que revivió en una audiencia del Senado el 5 de febrero de 2025. En los últimos años, Kennedy se ha posicionado como un crítico vocal de las políticas de vacunación, cuestionando el consenso científico y promoviendo escepticismo hacia las vacunas. Esto ha generado una polarización significativa, con seguidores que ven en él un defensor de la libertad individual y críticos que lo acusan de difundir desinformación. Sus libros, como “Timerosal: Que hable la ciencia” (2014), reflejan su enfoque en los supuestos riesgos de los conservantes en vacunas. Kennedy es un charlatán que solo está redefiniendo el negocio de los laboratorios mientras engaña, esperanza e ilusiona a los ingenuos. En unas recientes declaraciones dijo sobre las vacunas covid que “no superan los beneficios supuestos”, además de mencionar la “falta de datos de alta calidad que demuestren la seguridad de las vacunas de ARNm durante el embarazo” y la incertidumbre en cuanto a los beneficios para las madres gestantes y sus bebés”. Pero como podemos ver en la web del CDC, Notas del calendario de vacunación infantil, se sigue vacunando a bebes a partir de los 6 meses contra una enfermedad imaginaria como es el covid, con vacunas que se ha visto que presentan muchas reacciones adversas. Independientemente de las palabras de Kennedy al final las mujeres embarazadas son "personas de riesgo" para el CDC y por tanto se las recomienda vacunarse del covid. La administración bajo el mandato de Kennedy ha dicho que «todas las nuevas vacunas se someterán a pruebas de seguridad en ensayos controlados con placebo antes de su autorización», sin embargo la FDA acaba de aprobar una nueva inyección de Moderna sin un solo ensayo controlado con placebo. Los estudios con placebo empezarían a finales de este año y concluirían en 2027, pero la vacuna mNexspike de baja dosis ya esta en el mercado para personas de 65 años o mas o entre los 12 y 64 con al menos uno o más factores de riesgo subyacentes. Es más, Kennedy está permitiendo que siga la investigación para encontrar vacunas a la carta. Al respecto dijo: ”Un impulso para sustituir las vacunas de talla única por vacunas genéticamente personalizadas que sean seguras y eficaces para todos”. Leemos en una nota de prensa del Departamento de Salud y Servicios Humanos (HHS) del pasado 1 de mayo lo siguiente: “Washington, D.C. - Departamento de Salud y Servicios Humanos (HHS) y los Institutos Nacionales de Salud (NIH) anunciaron hoy el desarrollo de la plataforma de vacunas universales de próxima generación, Generation Gold Standard, utilizando una plataforma de beta-propioctona (BPL) activada por todovirus. Esta iniciativa representa un cambio decisivo hacia la transparencia, la eficacia y la preparación integral, financiando el desarrollo interno de vacunas universales contra la gripe y el coronavirus de los NIH, incluidos los candidatos BPL-1357 y BPL-24910. Estas vacunas tienen como objetivo proporcionar una protección de amplio espectro contra múltiples cepas de virus propensos a pandemias como la gripe aviar H5N1 y los coronavirus como SARS-CoV-2, SARS-CoV-1, y MERS-CoV. Nuestro compromiso es claro: toda innovación en el desarrollo de vacunas debe basarse en la ciencia y la transparencia del patrón oro, y sometida a los más altos estándares de pruebas de seguridad y eficacia, dijo el secretario del HHS, Robert F. Kennedy, Jr.” Nos están hablando no solo del covid, si no de la gripe aviar y el virus MERS… En abril de 2024, Kennedy lanzó una campaña para la nominación presidencial del Partido Demócrata, pero en octubre de ese año anunció que correría como independiente, rompiendo con el partido al que su familia ha estado históricamente vinculada. Su campaña se centró en temas como la libertad individual, la transparencia gubernamental y la reforma del sistema de salud, pero enfrentó desafíos en términos de apoyo y cobertura mediática. El 23 de agosto de 2024, suspendió su campaña y respaldó a Donald Trump en un mitin en Arizona, con la intención de mantener su presencia en la boleta en estados no competitivos. Este movimiento fue visto como una estrategia para influir en la política nacional, especialmente en temas de salud. El 14 de noviembre de 2024, Donald Trump lo nominó para el cargo de Secretario de Salud y Servicios Humanos (HHS), un puesto que asumió el 13 de febrero de 2025, tras una confirmación ajustada en el Senado con un voto de 52 a 48, donde Mitch McConnell fue el único republicano en votar en contra. Este nombramiento marcó un hito, ya que Kennedy se convirtió en el primer candidato presidencial independiente en ocupar un puesto de gabinete después de postularse para la presidencia. Su confirmación enfrentó oposición, con más de 17,000 médicos firmando una carta en enero de 2025 instando al Senado a rechazar su nominación, reflejando las preocupaciones sobre sus posturas en salud pública. Robert F. Kennedy Jr., al asumir el cargo de secretario de Salud y Servicios Humanos (HHS), poseía una cartera de inversión considerable que incluía acciones en empresas que, en teoría, debería regular en su rol. Según una carta de información presentada el 21 de enero de 2025, a pocos días de asumir su cargo, ante la Oficina de Ética Gubernamental de Estados Unidos, RFK Jr. se comprometió a desinvertir en varias compañías, incluidas las biotecnológicas CRISPR Therapeutics y Dragonfly Therapeutics, en un plazo de 90 días si era confirmado para el puesto. El invertía en empresas de terapias genéticas tales como CRISPR Therapeutics y Dragonfly mientras advertía de los riesgos de esas mismas terapias a través de su Fundación Children's Health Defens, en lo que consideramos una acción hipócrita. Un documento separado detalla un extenso listado de relaciones económicas, que incluye inversiones en empresas destacadas como Amazon, Apple, Vanguard, Citibank, Deutsche Bank, Rockefeller Access Fund, Disney, Warner Bros, entre otras, evidenciando la magnitud de su portafolio. Desde su toma de posesión, Kennedy ha implementado una serie de políticas controvertidas. El 13 de febrero de 2025, firmó la Orden Ejecutiva 14211, creando la Comisión "Make America Healthy Again" (MAHA), que preside, con el objetivo de investigar las enfermedades crónicas infantiles y evaluar las amenazas de los medicamentos con receta. El 22 de mayo de 2025, lanzó el informe MAHA, que posteriormente fue criticado por contener citas a estudios inexistentes, con la Casa Blanca atribuyendo los errores a problemas de formato. El 29 de mayo de 2025, se informó que su equipo agregó nuevos errores al informe, empeorando la situación. Otras acciones incluyen el despido de aproximadamente 5,200 trabajadores federales de salud recién contratados de agencias como los CDC y el NIH el 14 de febrero de 2025, y la eliminación de la mayoría del personal del Instituto Nacional para la Seguridad y Salud Ocupacional en abril de 2025, cancelando programas como las aprobaciones de equipos de seguridad para el lugar de trabajo y la investigación sobre la salud de los bomberos. El 9 de junio de 2025, removió a los 17 miembros del Comité Asesor sobre Prácticas de Inmunización (ACIP) de los CDC y los reemplazó con nuevos miembros, una decisión que generó críticas por potenciales conflictos de interés. El 20 de febrero de 2025, instruyó a los CDC a suspender las campañas publicitarias de vacunación contra la gripe durante una temporada de influenza severa, enfocándose en el "consentimiento informado". Durante un brote de sarampión en el suroeste de los Estados Unidos en 2025, que reportó 146 casos, 20 hospitalizaciones y 1 muerte en Texas a finales de febrero, Kennedy hizo comentarios públicos el 26 de febrero de 2025, afirmando falsamente que hubo dos muertes y cuatro brotes ese año (16 en 2024), y sugirió que la cuarentena fue la principal razón de las hospitalizaciones, lo cual fue refutado. Promovió tratamientos marginales como el aceite de hígado de bacalao y la vitamina A, y escribió un artículo de opinión en Fox News el 2 de marzo de 2025, calificando a las vacunas de "elección personal" y recomendando vitaminas, lo que llevó a informes de toxicidad por vitamina A en niños infectados. El 28 de marzo de 2025, enfrentó más críticas por promover tratamientos no convencionales, como vitaminas, lo que generó alarma entre los profesionales de la salud. El 25 de marzo de 2025, su desinformación llevó a la renuncia del principal encargado de la comunicación de salud pública de los CDC, y el 3 de marzo de 2025, el principal portavoz de HHS también renunció, citando "desinformación y mentiras". El 28 de marzo de 2025, el principal oficial de vacunas de la FDA también renunció por razones similares. En julio de 2025, Kennedy enfrenta demandas legales significativas. El 7 de julio de 2025, la Academia Americana de Pediatría, la Asociación Americana de Salud Pública y otras organizaciones médicas demandaron a HHS y a Kennedy por cambios unilaterales en las recomendaciones de vacunas, específicamente por eliminar las recomendaciones de vacunas contra el COVID-19, argumentando que estas acciones son ilegales. Estas demandas reflejan la creciente oposición de la comunidad médica a sus políticas. Además, el 25 de junio de 2025, acusó a Gavi, una agencia global de vacunas, de ignorar la ciencia en la inmunización de niños, una afirmación que ha sido controvertida y criticada por expertos. Robert F. Kennedy Jr. elogió recientemente la Operación Warp Speed, (lanzada en mayo de 2020, bajo la administración de Donald Trump, con el objetivo de acelerar el desarrollo, la producción y la distribución de vacunas, tratamientos y diagnósticos para la COVID-19), calificándola de "logro extraordinario" y "demostración de liderazgo" del expresidente Donald Trump. Esta declaración supone un cambio notable para Kennedy, que anteriormente había criticado la iniciativa. Sus comentarios se realizaron durante una audiencia en el Senado, destacando las complejidades de la lealtad política y la evolución de las narrativas que rodean el despliegue de la vacuna COVID-19 de la administración Trump. Las acciones de Kennedy como Secretario de HHS han generado un debate intenso sobre el equilibrio entre la libertad individual y la responsabilidad pública en salud. Su promoción de la iniciativa MAHA, incluyendo giras por estados como Oklahoma y Louisiana en julio de 2025, busca revolucionar el sistema de salud, pero muchos lo ven como una fuente de temor por su enfoque en teorías marginales y su rechazo al consenso científico. Su legado como activista ambiental sigue siendo notable, como dijimos fue miembro y directivo del grupo ambientalista Riverkeeper. El bagaje de esta ONG inspiró un libro cuyo prologo fue escrito por el también promotor de los créditos de carbono Al Gore. Robert Kennedy es un calentólogo que dio un discurso durante el concierto de la misma temática catastrofista llamado Live Earth que organizó David Rothschild y Al Gore entre otros. Robert F. Kennedy Jr durante “la Marcha Popular por el Clima” en Nueva York que se llevó a cabo el domingo 21 de septiembre de 2014 dijo: “que es lamentable que no existan leyes para reducir el escepticismo sobre el cambio climático entre los legisladores” y “"Ojalá existiera una ley que los castigara”. ¿No tiene ojos en la cara el señor Kennedy para ver que la geoingeneria está detrás del supuesto cambio climático? El ayuntamiento de Adeje, en la isla de Tenerife, le pago una visita para hablar sobre el cambio climático. Un ayuntamiento de un pueblo de 50.000 habitantes trae a una superestrella como el señor Kennedy para que les cuente una milonga que solo han visto unas 100 personas en Youtube. Les pondremos la charla en la descripción del podcast. Y es que hay mucho dinero para este tipo de campañas que en realidad promueven la Agenda 2030 al igual que otras supuestas luchas como la libertad sexual. RFK Jr. ha sido un luchador por la comunidad LGBT y el "matrimonio igualitario". En 2011 se unió a su Campaña de Derechos Humanos en Nueva York junto a Mike Bloomberg, Fren Drescher, Kevin Bacon, Whoopi Goldberg y otros. Es una marioneta mas del poder al igual que lo fue su tio o cualquier otro miembro de la familia Kennedy. El New York Post lo relacionó presuntamente con Epstein y el Lolita express, en un largo y documentado artículo publicado en diciembre de 2023. No solo muestra una fotografía de RFK Jr. y su amante durante una fiesta que ofreció Epstein en 1994 si no que recoge declaraciones del propio Kennedy reconociendo que viajo por lo menos dos veces en el avión del pederasta en compañía de niños. Su amante por aquel entonces que luego terminaría siendo su esposa, Mary Richardson Kennedy, se suicidó en 2012 dos años después de divorciarse de Kennedy. Por aquel entonces estaban empezando a salir a la luz los escándalos de Epstein. En el New York Post podemos leer: “Kennedy era tan cercano a Epstein que el multimillonario tenía una larga entrada para “Kennedy, Bobby y Mary” en su “pequeña libreta negra”, que incluía contactos de personas de la alta sociedad y políticos, así como de las jóvenes a las que agredió sexualmente.” Christina Oxenberg miembro de la depuesta familia real serbia (el príncipe Andrés de Gran Bretaña es primo segundo), es una vieja amiga de la familia Kennedy y escribió un libro en 2021 donde habla de esa relación: “Esos viajes tuvieron lugar hace aproximadamente 30 años, mucho antes de que la conducta criminal del Sr. Epstein fuera de conocimiento público”. “En junio de 1989, el magnate de la prensa británica Robert Maxwell organizó una fiesta en el Lady Ghislaine, a orillas del Potomac, en Washington, D. C. Entre los invitados se encontraban el reverendo Jesse Jackson, exsecretario de Defensa, el director de la CIA y dos Kennedy.” Robert Maxwell era el padre de la compinche de Epstein, la supuesta madame, que atraía y manejaba a las chicas jóvenes con las que Epstein chantajeaba a la flor y nata mundial. Una Doctora que huyó a México estuvo denunciando a este particular Kennedy de que le estaba enviando acoso mafioso organizado e intentos de asesinato con tipos de la C I A. Esto durante la plandemia, antes de ingresar como miembro del "gobierno" actual de USA. Por supuesto este tipo de noticias son tildadas de bulo por las agencias verificadoras. Pero conozcamos un poco de dónde vienen estas agencias. Y es que la CIA, las agencia de verificación y los Kennedy son como uña y carne como se puede ver en documentos desclasificados de la propia CIA. Desde 1985 la CIA planeó como introducir sus ideas en el público. Para ello se infiltró junto al FBI en varias universidades como la Escuela de Gobierno Kennedy de Harvard. Desde allí se empezaron a crear las primeras agencias de fact checking como Crosscheck y otras bajo agencias como First Draft...agencia cuya supervisión recae en la propia CIA. Para Maldita.es la verdad brota de estas fuentes. Como os digo la propia CIA dio una conferencia en 1987 para dejar claro que las mentes más privilegiadas debían compartir pupitre con algunos de sus agentes. Esto es ya es duro de por si...pero aún no es nada para lo que esconden estas agencias de verificación. Una pequeña búsqueda os arrojará quién está detrás de la financiación de las principales. Incluyendo las españolas maldito bulo y otras. Las Fundaciones Avina y Ashoka son sus principales garantes. Nuestros amigos de Desmontando a Babylon nos lo contaron en varias ocasiones como en BdlV - dab radio temporada 7.0 Episodio 03 No somos m ashokas Clara Jiménez Cruz, la cofundadora y CEO de Maldito Bulo fue elegida Ashoka Fellow (una changemaker) en 2019. ¿Qué es eso de Ashoka y de que va ese tema de los changemakers, los hacedores del cambio o emprendedores sociales? Básicamente hablamos de unas cuantas familias poderosas, entre ellas la suiza Schmidheiny y la belga Emsens y De Cartier, todas ellas propietarias de las multinacionales que explotaron el amianto, creando y financiando estas agencias de verificación con la complicidad, como no, de los Estados Unidos. Así que ya veis, las multinacionales que contaminaron con amianto todo el mundo occidental y que han provocado cientos de miles de muertes por cáncer están detrás de las agencias que verifican si la información es real. De esto no oiréis hablar nunca al flamante RFK Jr. Estamos ante un político que habla sin dejar clara su postura en muchos puntos importantes, por ejemplo, durante su comparecencia en la audiencia del 29 de enero de 2025 para considerar su nominación como Secretario de Salud y Servicios Humanos le hicieron esta pregunta sobre la IA: “La inteligencia artificial está transformando la investigación, el desarrollo y la prestación de servicios sanitarios. Tiene el potencial de mejorar la atención al paciente, los resultados sanitarios y la eficiencia. La IA también podría ser utilizada por los pagadores para limitar el acceso de los pacientes y crear obstáculos adicionales. ¿Qué papel cree que desempeñará el HHS en la gobernanza de esta tecnología transformadora?" Y esta fue su respuesta: “La inteligencia artificial tiene el potencial de cambiar fundamentalmente la forma en que se prestan los servicios sanitarios y los servicios humanos. Teniendo esto en cuenta, es posible que sea necesario considerar nuevas políticas y enfoques en toda la industria y el gobierno. El HHS puede apoyar mejor a los pacientes ofreciendo un entorno regulatorio claro y estable, cuando sea apropiado, con respecto a la seguridad, la eficacia y la transparencia, al tiempo que crea un amplio espacio para que el sector privado innove y amplíe la competitividad de Estados Unidos.” Le preguntaron sobre la transparencia. “Sr. Kennedy, la primera administración Trump tomó medidas importantes para mejorar la transparencia en la atención médica. Los programas y requisitos de transparencia en la atención médica, si se amplían, podrían ofrecer una oportunidad única para ayudar de manera significativa a reducir los costos de la atención médica y mejorar la calidad de los resultados. Si se confirma su nombramiento, ¿seguirá apoyando estos esfuerzos mediante la implementación de programas piloto de transparencia adicionales y políticas del HHS para ampliar aún más el trabajo que el gobierno federal ya ha comenzado en materia de transparencia?” Respuesta: R: “Si se confirma mi nombramiento, me comprometo a instaurar la transparencia en todos los programas y actividades del HHS, para que los estadounidenses puedan recuperar la confianza en el sistema sanitario. Además, espero con interés trabajar con el Congreso para presentar reformas legislativas que proporcionen a los estadounidenses una transparencia sin precedentes en su sistema sanitario.” Le preguntaron por la pandemia de Covid y se limito a contestar como lo haría un político. “La pandemia de COVID-19 puso de relieve el papel fundamental de la telesalud, que permite a los pacientes mantenerse en contacto con sus equipos de atención médica mientras permanecen seguros en sus hogares. Pero más allá de la pandemia, la telesalud sigue ofreciendo esperanza e innovación, desde el apoyo a los servicios de salud mental hasta la gestión de enfermedades crónicas, la mejora de la atención materna e incluso la solución de la escasez de personal en el sector sanitario. Presenté la Ley de Modernización de la Telesalud, un proyecto de ley bipartidista para hacer permanentes las flexibilidades de telesalud promulgadas durante la pandemia de COVID-19, con el fin de garantizar la cobertura continua y el acceso a la atención médica para los estadounidenses. Si se confirma, ¿cómo planea el HHS trabajar con el Congreso para garantizar que millones de beneficiarios de Medicare no pierdan el acceso a los servicios de telesalud y caigan abruptamente en el «precipicio de la telesalud»?” Respuesta: “La telesalud es una herramienta importante para proporcionar acceso a una gama de servicios de atención médica cruciales, especialmente para quienes viven en zonas rurales y en áreas con escasez de proveedores. Si se confirma mi nombramiento, espero trabajar con el Congreso para garantizar que los modos innovadores de prestación de atención médica, como la telesalud, maximicen la calidad y el acceso a la atención para los beneficiarios de Medicare.” Y es que durante el Covid se gano mucho dinero sometiendo a la población a medidas tan absurdas como usar un bozal que no servia para nada. Tenemos un escándalo en España que relaciona a la oficina de la Fundación Human Rights que dirige Kennedy con este tema de las mascarillas. El hijo de Nati Abascal se compró entre otras cosas un yate de 13 metros de eslora con sus comisiones. Encima bautizó a la embarcación como Feria en honor al titulo nobiliario que ostenta la familia, el del famoso pederasta Duque de Feria. Fue la presidenta de la universidad americana CIS, María Díaz de la Cebosa que es a la vez la persona que lleva en España la fundación Human Rights que preside Kennedy la que le facilitó al imputado Luis Medina el teléfono de Carlos Martínez-Almeida, el primo del alcalde de Madrid, José Luis Martínez-Almeida. Los dos empresarios imputados se llevaron 6 millones de euros de un contrato para la compra de material sanitario. El hijo de Naty Abascal y su exsocio, absueltos de estafar al Ayuntamiento de Madrid, todo quedo en agua de borrajas. Le preguntan sobre el SIDA y responde esto: “El presupuesto anual del Instituto Nacional de Alergias y Enfermedades Infecciosas impulsa investigaciones fundamentales; entre los ejemplos se incluyen el desarrollo exitoso de nuevas vacunas contra el VRS, un fármaco aprobado por la FDA que retrasa la aparición de la diabetes tipo 1, una vacuna de ARNm contra el VIH y mucho más. Explique por qué planea detener este trabajo y a quién beneficiará.” Respuesta: “Si se confirma mi nombramiento, espero evaluar todas las agencias y programas para asegurarme de que están cumpliendo la misión de devolver la salud a los estadounidenses.” Las agencias de verificación son un invento, como hemos visto antes, de las grandes multinacionales y estas mismas empresas siguen trabajando sin cortapisas bajo la administración de este supuesto antivacunas que no lo es tal. Estas agencias no nos contaran la verdad jamas y no hablaran de la relación de este Kennedy con los grupos antivacunas que promocionan en verdad la Agenda 2030 y la Nueva era. Ni de esto ni de la La trágica historia de Rosemary, la hermana de J.F. Kennedy a quien su padre mandó a lobotomizar. Yo no me fiaría mucho de una familia que es capaz de realizarle una lobotomía a una pobre joven con problemas derivados de su nacimiento. En el parto no pudo respirar por no dejar que saliera de forma natural esperando casi dos horas por un médico que no llegaba. Una criada mantuvo las piernas cerradas de la madre… Hablamos de una joven con pequeños trastornos de aprendizaje que llegó a socializar con la realeza británica. Fue expulsada de Inglaterra por las declaraciones de su padre que afirmaba “que Reino Unido no podía ganar la guerra y que la democracia había terminado”. Regreso a USA y al final fue recluida en un convento...era incontrolable y una Kennedy incontrolable es un problema de estado. En un articulo de BBC news leemos: “Encerrada en un convento, se volvió desafiante a las restricciones. Las monjas no pudieron controlarla. "Muchas noches", recordó la prima de Rosemary, Ann Gargan, "la escuela llamaba a decir que había desaparecido y la encontraban vagando por las calles a las 2 a.m.". Pronto se supo que Rosemary se estaba escapando, según un compañero paciente que compartió muchos años del confinamiento posterior de Rosemary, para ir a tabernas y encontrarse con hombres en busca de atención, consuelo y sexo, escribió Elizabeth Koehler-Pentacoff en The Missing Kennedy.” Su padre tenía aspiraciones políticas para sus hijos y Rosemary era un peligro así que decidió someterla a una lobotomía con solo 23 años. Seguimos leyendo en BBC news: “Tras perforar agujeros en el cráneo de Rosemary, Freeman insertó un cuchillo y comenzó a cortar los lóbulos frontales de su cerebro. Atada a la mesa, ella estaba despierta y aterrorizada durante el procedimiento. De repente, se quedó en silencio y cayó en la inconsciencia. La operación había sido un catastrófico fracaso. Rosemary quedó sin poder caminar ni hablar. Incluso después de años de terapia, no podía pronunciar más que unas pocas palabras y nunca recuperó completamente el uso de sus extremidades.” Murió en 2005, a los 86 años tras pasar 63 largos años aislada, recluida en centros de internamiento privados sin recibir visitas. Si son capaces de hacer eso con uno de los suyos, que no serán capaces de hacer con un extraño. A continuación se presenta una lista de los principales eventos considerados parte de la «Maldición Kennedy». Si bien es improbable que todos estos eventos fueran resultado de una conspiración contra la familia, es difícil ignorar el fuerte patrón de sincronicidad, también conocido como «coincidencias significativas», asociado con los Kennedy. 1941—Se creía a menudo que Rosemary Kennedy padecía problemas mentales. Algunas fuentes afirmaban que padecía enfermedades mentales, como depresión y esquizofrenia. Debido a sus cambios de humor cada vez más violentos y severos, su padre, Joe Sr., organizó en secreto que se sometiera a una lobotomía. La lobotomía, en cambio, deterioró aún más sus capacidades cognitivas y, como resultado, Rosemary permaneció internada hasta su fallecimiento en 2005. 12 de agosto de 1944—Joseph P. Kennedy, Jr. murió cuando su avión explotó sobre East Suffolk, Inglaterra, como parte del Proyecto Anvil. 13 de mayo de 1948—Kathleen Cavendish, marquesa de Hartington, murió en un accidente aéreo en Francia. 23 de agosto de 1956: Jacqueline Bouvier Kennedy dio a luz a una hija muerta, Arabella. (Aunque está enterrada en el Cementerio Nacional de Arlington junto a sus padres con una placa que dice "Hija", sus padres tenían la intención de llamarla Arabella). 9 de agosto de 1963—Patrick Bouvier Kennedy murió dos días después de su nacimiento prematuro. 22 de noviembre de 1963—El presidente estadounidense John F. Kennedy fue asesinado en Dallas, Texas. Lee Harvey Oswald fue acusado del crimen, pero Jack Ruby lo mató a tiros dos días después, antes de que pudiera celebrarse el juicio. El FBI y la Comisión Warren concluyeron oficialmente que Oswald fue el único asesino. Sin embargo, el Comité Selecto de la Cámara de Representantes de Estados Unidos sobre Asesinatos (HSCA) concluyó que dichas investigaciones presentaban graves deficiencias y que Kennedy probablemente fue asesinado como resultado de una conspiración. 19 de junio de 1964—El senador estadounidense Edward M. “Ted” Kennedy sufrió un accidente aéreo en el que fallecieron uno de sus asesores y el piloto. Fue rescatado de los restos por su colega senador Birch E. Bayh II y pasó semanas hospitalizado recuperándose de una fractura de espalda, un pulmón perforado, costillas rotas y una hemorragia interna. 5 de junio de 1968—El senador estadounidense Robert F. Kennedy fue asesinado por Sirhan Bishara Sirhan en Los Ángeles, inmediatamente después de su victoria en las primarias presidenciales demócratas de California. Sirhan fue declarado culpable del asesinato de Kennedy y cumple cadena perpetua en el Centro Correccional Richard J. Donovan. 18 de julio de 1969—En el incidente de Chappaquiddick, Ted Kennedy se cayó accidentalmente de un puente en la isla de Chappaquiddick, atrapando fatalmente a su pasajera, Mary Jo Kopechne, en su interior. En su declaración televisada del 25 de julio, Kennedy afirmó que la noche del incidente se preguntó si realmente pesaba una terrible maldición sobre todos los Kennedy. 13 de agosto de 1973—Joseph P. Kennedy II era el conductor de un automóvil que se estrelló y dejó a su pasajera, Pam Kelley, paralizada. 25 de abril de 1984—David Anthony Kennedy murió de una sobredosis de cocaína y Demerol en una habitación de hotel de Palm Beach, Florida. 31 de diciembre de 1997—Michael LeMoyne Kennedy falleció en un accidente de esquí en Aspen, Colorado . Kennedy era sospechoso de estupro tras mantener una relación de tres años con una niñera de 14 años. 16 de julio de 1999—John F. Kennedy, Jr. falleció cuando la avioneta Piper Saratoga que pilotaba se estrelló en el océano Atlántico frente a la costa de Martha's Vineyard debido a un error del piloto. Su esposa y su cuñada también fallecieron. – Wikipedia, “La maldición de Kennedy” ………………………………………………………………………………………. Conductor del programa UTP Ramón Valero @tecn_preocupado Canal en Telegram @UnTecnicoPreocupado Un técnico Preocupado un FP2 IVOOX UTP http://cutt.ly/dzhhGrf BLOG http://cutt.ly/dzhh2LX Ayúdame desde mi Crowfunding aquí https://cutt.ly/W0DsPVq Invitados Dra Yane #JusticiaParaUTP @ayec98_2 Médico y Buscadora de la verdad. Con Dios siempre! No permito q me dividan c/izq -derecha, raza, religión ni nada de la Creación. https://youtu.be/TXEEZUYd4c0 ………………………………………………………………………………………. Enlaces citados en el podcast: AYUDA A TRAVÉS DE LA COMPRA DE MIS LIBROS https://tecnicopreocupado.com/2024/11/16/ayuda-a-traves-de-la-compra-de-mis-libros/ La vida oculta de los Kennedy: La dinastía de la élite que fue diezmada (Parte I) https://vigilantcitizen.com/vigilantreport/kennedys-elite-dynasty-got-decimated-pt/ La vida oculta de los Kennedy: La dinastía de la élite que fue diezmada (Parte II) https://vigilantcitizen.com/vigilantreport/hidden-life-kennedys-elite-dynasty-got-decimated-pt-ii/ La vida oculta de los Kennedy: La dinastía de élite diezmada (Parte III) https://vigilantcitizen.com/vigilantreport/hidden-life-kennedys-elite-dynasty-got-decimated-pt-iii/ Moderna consigue aprobación de la FDA para mNexspike, su vacuna COVID de baja dosis con acceso limitado https://www.infobae.com/estados-unidos/2025/06/01/moderna-consigue-aprobacion-de-la-fda-para-mnexspike-su-vacuna-covid-de-baja-dosis-con-acceso-limitado/ Kennedy es un charlatán que solo está redefiniendo el negocio de los laboratorios mientras engaña, esperanza e ilusiona a los ingenuos. Se sigue vacunando a bebes a partir de los 6 meses. https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-covid-19 Independientemente de las palabras de Kennedy al final las mujeres embarazadas son "personas de riesgo" para el CDC y por tanto se las recomienda vacunarse del covid. https://www.nejm.org/doi/full/10.1056/NEJMsb2506929 FDA aprueba nueva inyección de Moderna sin un solo ensayo controlado con placebo https://cienciaysaludnatural.com/fda-aprueba-nueva-inyeccion-de-moderna-sin-ensayo-controlado/ PowerPoint de Children's Health Defense "El público exige una vacuna Covid-19 segura". "Lo que muchos quieren realmente es un programa de vacunas seguras para todos, 𝗳𝗼𝗿 𝘆𝗼𝘂 𝗮𝗻𝗱 𝗺𝗲, 𝗳𝗼𝗿 𝗰𝗵𝗶𝗹𝗱𝗿𝗲𝗻, 𝗳𝗼𝗿 𝘆𝗼𝘂𝗿 𝗴𝗿𝗮𝗻𝗱𝗰𝗵𝗶𝗹𝗱𝗿𝗲𝗻." "Un impulso para sustituir las vacunas de talla única por 𝗴𝗲𝗻𝗲𝘁𝗶𝗰𝗮𝗹𝗹𝘆 "𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱" 𝗶𝗺𝗺𝘂𝗻𝗶𝘇𝗮𝘁𝗶𝗼𝗻𝘀 que sean seguras y eficaces para todos" Fuente de las diapositivas (13 y 54): https://childrenshealthdefense.org/protecting-our-future/covid-vaccine-safety-concerns/ Nota de prensa del Departamento de Salud y Servicios Humanos (HHS) del pasado 1 de mayo. Washington, D.C. - Departamento de Salud y Servicios Humanos (HHS) y los Institutos Nacionales de Salud (NIH) anunciaron hoy el desarrollo de la plataforma de vacunas universales de próxima generación, Generation Gold Standard, utilizando una plataforma de beta-propioctona (BPL) activada por todovirus. Esta iniciativa representa un cambio decisivo hacia la transparencia, la eficacia y la preparación integral, financiando el desarrollo interno de vacunas universales contra la gripe y el coronavirus de los NIH, incluidos los candidatos BPL-1357 y BPL-24910. Estas vacunas tienen como objetivo proporcionar una protección de amplio espectro contra múltiples cepas de virus propensos a pandemias como la gripe aviar H5N1 y los coronavirus como SARS-CoV-2, SARS-CoV-1, y MERS-CoV. Nuestro compromiso es claro: toda innovación en el desarrollo de vacunas debe basarse en la ciencia y la transparencia del patrón oro, y sometida a los más altos estándares de pruebas de seguridad y eficacia, dijo el secretario del HHS, Robert F. Kennedy, Jr. https://www.hhs.gov/press-room/hhs-nih-announces-generation-gold-standard.html Noticia de 11 de abril de 2025. La FDA aprueba vacuna de ARN mensajero contra la "gripe aviar". La FDA concedió la designación de vía rápida a una vacuna candidata de ARNm autoamplificante (ARCT-2304) para inmunización activa con el fin de proteger contra el subtipo H5N1 de la gripe A, también conocida como gripe aviar. La designación responde a la necesidad no cubierta de prevención del subtipo H5N1, que sigue siendo un riesgo sanitario mundial, y en noviembre de 2024 se inició un ensayo de fase 1 (NCT06602531) de la vacuna. https://www.drugtopics.com/view/fda-grants-fast-track-designation-for-potential-bird-flu-vaccine Robert Kennedy Jr invirtió en varias empresas de terapias genéticas tales como CRISPR Therapeutics y Dragonfly por un lado, mientras advertía de los riesgos esas mismas terapias a través de su Fundación Children's Health Defens por el otro. Dejo de participar en dichas empresas por los conflictos políticos que suponía su cargo sanitario en la Administración Trump no por conflictos éticos por su discurso contradictorio en Children's Health Defense. https://www.fiercebiotech.com/biotech/rfk-jr-will-divest-interests-crispr-tx-dragonfly-if-hhs-role-confirmed-letter Robert Kennedy es un calentólogo que dio un discurso durante el concierto de la misma temática catastrofista llamado Live Earth que organizó David Rothschild y Al Gore entre otros. https://youtube.com/watch?v=KG5zckBejK0&t=26s Robert F. Kennedy Jr. elogió recientemente la Operación Warp Speed, calificándola de "logro extraordinario" y "demostración de liderazgo" del expresidente Donald Trump. Esta declaración supone un cambio notable para Kennedy, que anteriormente había criticado la iniciativa. Sus comentarios se realizaron durante una audiencia en el Senado, destacando las complejidades de la lealtad política y la evolución de las narrativas que rodean el despliegue de la vacuna COVID-19 de la administración Trump. https://m.youtube.com/watch?v=xxOhOAXfjZw Robert F. Kennedy Jr: Los negacionistas del cambio climático deben ser castigados por ley Septiembre de 2014 https://www.al.com/news/2014/09/robert_f_kennedy_jr_climate-ch.html Robert Kennedy Jr presidió Waterkeeper, grupo ambientalista que acabó fusionándose con RiverKepper de la que también fue abogado. Ambas organizaciones fueron pioneras en reclamar la "restauración" de los ríos, un eufemismo que en realidad significa la destrucción de presas y otras infraestructuras hidráulicas y energéticas. Modelo que se ha replicado en todo el mundo golpeando especialmente a España. https://es.waterkeeper.org/revistas/volumen-14-n%C3%BAmero-2/deja-que-nuestros-r%C3%ADos-corran-libres/ Robert Kennedy Jr fue miembro y directivo del grupo ambientalista Riverkeeper. El bagaje de esta ONG inspiró un libro cuyo prologo fue escrito por el también promotor de los créditos de carbono Al Gore. https://en.wikipedia.org/wiki/The_Riverkeepers Robert Kennedy es un activista climático. Conferencia en español y en Adeje, Tenerife https://www.youtube.com/watch?v=GzW2APdiMJs RFK Jr. ha sido un luchador por la comunidad LGBT y el "matrimonio igualitario". En 2011 se unió a su Campaña de Derechos Humanos en Nueva York junto a Mike Bloomberg, Fren Drescher, Kevin Bacon, Whoopi Goldberg y otros. https://youtu.be/66DspDO3Oyo Una Doctora que huyó a Mexico estuvo denunciando a este particular Kennedy de que este tipo le estaba enviando Acoso mafioso organizado e intentos de asesinato con tipos de la C I A. Esto en etapa de plandemia, antes de ingresar como miembro del "Robierno" actual de Usa. se lo relacionó presuntamente con Epstein y el Lolita express, presuntamente señor juez, como diría Ramón. https://nypost.com/2023/12/08/news/pictured-robert-f-kennedy-jr-and-jeffrey-epstein/ Robert F. Kennedy Jr. retirará sus inversiones en dos biotecnológicas si es confirmado para dirigir el Departamento de Salud y Servicios Humanos (HHS). Como secretario de Sanidad, RFK Jr. dijo que desinvertiría en varias empresas -incluidas CRISPR Therapeutics y Dragonfly Therapeutics- en un plazo de 90 días, según una carta de información presentada el 21 de enero ante la Oficina de Ética Gubernamental de Estados Unidos. Otras empresas de la lista son Amazon y Apple. La carta que se refiere es esta: https://extapps2.oge.gov/201/Presiden.nsf/PAS+Index/F3C8425ED335BB5685258C1A00565D57/$FILE/Kennedy%2C%20Jr.%2C%20Robert%20F.%20%20AMENDED%20finalEA.pdf Y este es el documento separado donde declara un listado de relaciones económicas. Llama la atención los nombres de Vanguard, City Bank, Deustsche Bank, Rockefeller Access Fund, Disney, Warner Bros, etc https://extapps2.oge.gov/201/Presiden.nsf/PAS+Index/A56222F259495B0D85258C1A00565073/$FILE/Kennedy%2C%20Jr.%2C%20Robert%20F.%20%20AMENDED%20final278.pdf La trágica historia de Rosemary, la hermana de J.F. Kennedy a quien su padre mandó a lobotomizar https://x.com/tecn_preocupado/status/1299723370892857344 La CIA en la escuela de gobierno Kennedy de Harvard https://x.com/tecn_preocupado/status/1781965457458712761 Audiencia para considerar la nominación de Robert F. Kennedy, Jr., de California, como Secretario de Salud y Servicios Humanos https://www.finance.senate.gov/hearings/hearingto-consider-the-nomination-of-robert-f-kennedy-jr-of-california-to-be-secretary-of-health-and-human-services María Díaz de la Cebosa, el supuesto 'enlace' entre Luis Medina y el primo de Almeida, admite que les puso en contacto https://cadenaser.com/2022/05/09/declara-maria-diaz-de-la-cebosa-el-supuesto-enlace-entre-luis-medina-y-el-primo-del-almeida-en-el-caso-mascarillas/ El yate que compró el hijo de Naty Abascal con la comisión de las mascarillas para Madrid https://www.elindependiente.com/espana/2022/04/06/el-yate-que-compro-el-hijo-de-naty-abascal-con-la-comision-de-las-mascarillas-para-madrid/ "Caso mascarillas": el hijo de Naty Abascal y su exsocio, absueltos de estafar al Ayuntamiento de Madrid https://www.larazon.es/madrid/caso-mascarillas-hijo-naty-abascal-exsocio-absueltos-estafar-ayuntamiento-madrid_2025031967da93fc6e9585000103b2e5.html Diagrama falsa disidencia anti vacunas https://t.me/MiVidaMiOxigeno/13790 ………………………………………………………………………………………. Música utilizada en este podcast: Tema inicial Heros Epílogo El Último de la Fila - Lejos de las leyes de los hombres (Versión 2023) https://www.youtube.com/watch?v=_tkV4PmfJx4

Research funded by the federal government has been crucial in many of the defining technologies of our time: the internet, A.I., crispr, Ozempic, and the mRNA vaccines first used widely in the COVID pandemic. Between 2010 and 2019, more than 350 drugs were approved in the United States, and virtually all of them could trace their roots to the National Institutes of Health (NIH). Now this administration is endangering our health by cutting funds to academic medical centers. Moreover, there are threats to Medicaid, as well as ongoing cuts to the Centers for Disease Control (CDC). Many universities have paused hiring due to the uncertainty at the NIH and are curtailing graduate programs. Biotech investors are warning of a contraction in medical innovation. NIH grants have been terminated on ideological grounds, which have resulted in clinical trials shutting down. Global health programs worldwide have been cut. A discussion on these destructive policies on medicine in our country is needed. About the Speaker Monica Gandhi M.D., M.P.H., is a professor of medicine and associate chief in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco (UCSF). She is also the director of the UCSF Center for AIDS Research (CFAR) and the medical director of the HIV Clinic ("Ward 86") at San Francisco General Hospital. She serves as the associate program director of the ID fellowship at UCSF. Her research focuses on HIV treatment and prevention optimization, HIV and women, adherence measurement in HIV and TB, adherence interventions, and on optimizing the use of long-acting antiretroviral therapy (ART). She is a long-standing NIH-funded researcher. Commonwealth Club World Affairs of California is a nonprofit public forum; we welcome donations made during registration to support the production of our programming. A Health & Medicine Member-led Forum program. Forums and Chapters at the Club are organized and run by volunteer programmers who are members of The Commonwealth Club, and they cover a diverse range of topics. Learn more about our Forums. Commonwealth Club World Affairs is a public forum. Any views expressed in our programs are those of the speakers and not of Commonwealth Club World Affairs. OrganizerMichael Baker  Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Duane Schulthess is joined by Sam Rasty, Chief Business Officer at Sensorium Therapeutics, Steve Potts, Chair of the Drug Development Council at the International Cancer Advocacy Network, and Joe Hammang, neuroscientist and US Business Director at Vital Transformation, to discuss how U.S. health policy is reshaping neuroscience innovation, investment priorities, and patient access. Key Topics:- Investment and R&D Strategy Shifts: Explore how the Inflation Reduction Act’s pricing controls and Medicare negotiations change venture capital allocation and steer neuroscience pipelines.- Patient Advocacy and Access Barriers: Guests discuss how formulary rules, generic-first requirements, and uneven advocacy across diseases affect drug adoption and innovation incentives.- Neuroscience Development Hurdles: The discussion highlights how social stigma around psychiatric conditions, fragmented orphan-disease incentives, and small-molecule exclusivity gaps slow CNS drug progress.- Legislative Fix Imperatives: Contributors outline proposed solutions such as the EPIC Act and expanded orphan-designation policies aimed at restoring balanced incentives for novel therapies.- Ecosystem Collaboration: The conversation covers the essential partnership between NIH funding, biotech startups, and pharmaceutical companies in advancing drugs from discovery to patients. This episode examines the policy, economic, and social factors influencing neuroscience drug discovery and the importance of communicating biotech’s value. It also highlights the need to improve the biotech narrative so that policymakers and the public understand its contributions. It is essential listening for industry leaders, investors, policymakers, and patient advocates seeking insight into innovation challenges and solutions.See omnystudio.com/listener for privacy information.

Aujourd'hui, Coach Lee & Coach Sim reçoivent Jessy Chabot Lessard, sexothérapeute.Dans cet épisode, nous discutons de:- Comment l'activité physique & la santé sexuelle sont intimement reliées- Comment le sport en excès peut nuire à la santé sexuelle- Comment les jouets sexuels sont souvent mal introduits- La différence entre un manque de libido et un manque de désir- Comment les produits anabolisants peuvent nuire à la santé sexuelle- Bien plus!Bonne écoute!Pour nous suivre:Jessy: @jessy_chabot.lessard & @sexocoachCoach Lee: @coach.lee__ Coach Sim: @coachsim.lat Utilisez le code "WUACV10" pour économiser 10% sur votre commande NIH sur le site ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://nihsupp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Utilisez le code "WUACV10" pour économiser 10% sur votre commande MACHINE sur le site https://project-machine.com/

Send us a textDid you know that the trillions of microbes in your gut could be the key to weight loss, better energy, fewer aches and pains - and even reversing chronic disease? In this episode, gut health pioneer Martha Carlin joins Coach Kevin to break down why your microbiome is the hidden root of so many modern health issues - and what you can do to restore it.  Whether you're dealing with bloating, fatigue, brain fog, or stubborn weight that just won't budge - this conversation will give you a fresh (and hopeful) perspective on what's really going on inside your body. And more importantly - how to fix it. 

Dr. Joseph J. Burrascano Jr., a pioneer in the field of Lyme, began his practice in East Hampton, NY, in 1981, where he identified and detailed the clinical aspects of Lyme in a high-prevalence area. Renowned for his groundbreaking diagnostic and treatment guidelines since 1984, he has advised the CDC, NIH, and U.S. Senate, authored extensive publications, and is a founding member of ILADS, continuing to educate globally.

BUFFALO, NY - July 16, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on July 9, 2025, titled “A novel anti-human CD25 mAb with preferential reactivity to activated T regulatory cells depletes them from the tumor microenvironment.” In this study, researchers from the National Institute of Allergy and Infectious Diseases, led by first author Maja Buszko and corresponding author Ethan M. Shevach, discovered a new monoclonal antibody that selectively targets a subset of immune cells called regulatory T cells (Tregs). These cells, while normally important for preventing autoimmunity, also can block the body's ability to fight cancer by suppressing anti-tumor immune responses. This discovery could lead to novel cancer therapies that strengthen the immune system's capacity to attack tumors. The researchers identified an anti-CD25 monoclonal antibody with several atypical properties and named it 2B010. To evaluate its effects, they used humanized mice, laboratory mice that are engineered to carry human immune cells, to closely mimic how human immune systems respond to cancer. The treatment of these mouse models with 2B010 significantly decreased the number of Tregs in tumors and boosted the activity of CD8+ T cells, which are essential for killing cancer cells. Importantly, 2B010 worked without disrupting other key immune functions. Unlike traditional Anti-CD25 antibodies, it did not interfere with interleukin-2 (IL-2) signaling, which is essential for the growth and activity of effector T cells that fight cancer. “2B010 also had no effect on IL-2 induced STAT5 phosphorylation or CD4+ T cell proliferation in vitro while both were blocked by Clone D1 further supporting the view that 2B010 does not recognize the IL-2 binding site.” This finding is especially significant because high levels of Tregs in tumors are associated with poor outcomes in many cancers. By specifically removing these cells, 2B010 may help overcome one of the main barriers to current immunotherapy approaches. Its ability to preserve IL-2 signaling could also make it safer and more effective when used alone or in combination with existing therapies such as immune checkpoint inhibitors. While the 2B010 antibody showed strong effects in reducing Tregs and boosting immune cell activity, the study did not observe changes in tumor size in these models. Researchers suggest this may be due to limitations in the preclinical systems used, such as the lack of tumor-specific T cells in humanized mice. Nevertheless, these findings demonstrate that 2B010 has a unique mechanism of action that could complement other cancer immunotherapies in future clinical trials. In conclusion, the development of 2B010 is a promising step toward selectively disrupting the immune suppressive environment in tumors. As researchers continue to refine and test this antibody, it could become a powerful tool for enhancing the effectiveness of cancer treatments and improving outcomes for patients. DOI - https://doi.org/10.18632/oncotarget.28752 Correspondence to - Ethan M. Shevach - eshevach@Niaid.NIH.gov Video short - https://www.youtube.com/watch?v=2NJcGsI7WXA Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28752 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, Treg, CD25, TME, mAb, GVHD To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

1. Senator Rand Paul's Criminal Referral of Dr. Anthony Fauci Context: Senator Paul has reissued a criminal referral to the DOJ against Dr. Fauci, citing perjury related to his 2021 Senate testimony on gain-of-function research in Wuhan. Controversy: The referral is tied to President Biden’s use of an autopen to sign pardons, including one for Fauci. If the autopen-signed pardons are ruled invalid, Fauci could face prosecution. Allegations: Fauci allegedly misled Congress about NIH funding for gain-of-function research. Political Angle: The Trump administration is portrayed as cooperative in pursuing the investigation, while the Biden administration is accused of obstruction. 2. Supreme Court Ruling on the Department of Education Issue: The Trump administration’s plan to shut down the Department of Education and return control to the states. Ruling: The Supreme Court (6-3 decision) lifted an injunction, allowing layoffs of over 1,300 employees and enabling the department’s closure to proceed. Reactions: Supporters: Frame it as a win for parents, students, and educational reform. Dissenters: Warn of executive overreach and erosion of separation of powers. Next Steps: Programs like special education and student loans are being transferred to other federal agencies. Please Hit Subscribe to this podcast Right Now. Also Please Subscribe to the Ben Ferguson Show Podcast and Verdict with Ted Cruz Wherever You get You're Podcasts. Thanks for Listening #seanhannity #hannity #marklevin #levin #charliekirk #megynkelly #tucker #tuckercarlson #glennbeck #benshapiro #shapiro #trump #sexton #bucksexton#rushlimbaugh #limbaugh #whitehouse #senate #congress #thehouse #democrats#republicans #conservative #senator #congressman #congressmen #congresswoman #capitol #president #vicepresident #POTUS #presidentoftheunitedstatesofamerica#SCOTUS #Supremecourt #DonaldTrump #PresidentDonaldTrump #DT #TedCruz #Benferguson #Verdict #maga #presidenttrump #47 #the47morningupdate #donaldtrump #trump #news #trumpnews #Benferguson #breaking #breakingnews #morningupdateYouTube: https://www.youtube.com/@VerdictwithTedCruzSee omnystudio.com/listener for privacy information.

Last week, Abdul El-Sayed sat down with Donna to discuss his candidacy for the U.S. Senate!Abdul is running for the U.S. Senate because he believes life in Michigan shouldn't be this hard — or this expensive. After a successful career of making government work for Michiganders, he wants to take his vision to Washington and make the United States Senate work for you. He was born and raised in southeast Michigan and proudly attended public schools where he captained his high school football, wrestling, and lacrosse teams. Abdul was raised by his father, Mohamed, an Egyptian immigrant, and his stepmom, Jackie, whose family has lived in Gratiot County, Michigan, since the 1800s. he graduated from the university of michigan with the highest distinction and played on the wolverines men's lacrosse team. Abdul earned his medical degree from Columbia University on an NIH-funded fellowship and a second doctorate at Oxford University as a Rhodes Scholar. Abdul currently lives in Ann Arbor with his wife, Sarah, and their two brilliant young daughters, Emmalee and Serene.To learn more about Adbul El-Sayed and his vision for Michigan, click here.Support the showFollow us on Instagram, Facebook and Twitter.

At the 2025 ATS International Conference, Joshua Fessel, MD, PhD, ATSF, formerly of the NIH, and Shade Afolabi, MD, a pediatric pulmonologist practicing in Texas, sat down to discuss the extensive ramifications the cuts to the NIH caused researchers, clinicians, and patients. With host Erika Moseson, MD, MA, they explore the effects of losing funding on critical research projects, how patient families have been dealing with pauses on disease research, and how the field can help retain and support early career professionals affected by these policy decisions. Did you miss the ATS 2025 International Conference? Or were you unable to attend some key sessions? Go to conference.thoracic.org/program/conference-highlights/ to purchase your ATS Conference Highlight Package. Be sure to check out the Out of the Blue podcast from the American Journal of Respiratory and Critical Care Medicine, which takes you out of the pages of the Blue Journal and into the minds of the most brilliant researchers in the fields of respiratory, critical care, and sleep medicine. Tune in wherever you listen to podcasts! 

Dr. Laura welcomes Kirkland Shave, co-founder of the Mountain Trek health reset retreat, and Dr. Kelly Tremblay, neuroscientist and certified coach, to Where Work Meets Life™to explore the connection between holistic health, burnout prevention, and the mind-body connection. Kelly and Kirk discuss the prevalence of stress and burnout in today's society and our lack of meaningful connection to nature and our own bodies and minds. Dr. Laura investigates these issues from a neurological perspective and a practical wellness approach with both Kelly and Kirk, learning what can be done to reset our healing.Forest bathing, flow trekking and sensory health practices that involve engaging with sound, scent, and visual natural experiences are all part of the conversation. Connecting with our senses and the reality of nature while separating ourselves from screens and demands can dramatically reduce stress and enhance brain function. While Kelly shares neuroscience research linking stress to actual structural brain changes, Kirk offers transformative stories from Mountain Trek, where guests can unplug from digital overload. Dr. Laura highlights the importance of understanding the causes of our burnout and how we can take control to heal our body and mind.“You've probably heard about it's Shinrin-yoku, a Japanese-researched way of being moment to moment, mindful of the sensorial information that's coming through our sense organs into the brain. And you're doing that in nature, and you're in a state of flow… where you're not thinking about other things. You're paying attention to what do I see? Or what do I see in motion in front of me? Or what do I hear out of this ear versus this ear? Or what do I smell as I go by the bark of this tree? Or which direction is the sun landing on my skin? These moment-to-moment awarenesses have been proven to lower the stress hormone cortisol. The Japanese researched this, and the main reason why they did this research is because in the 80s, as the tech industry took off in Japan, people were working 12-hour days already that we're working now, and the work burnout was through the roof.” - Kirkland ShaveAbout Kirkland Shave:Kirkland Shave, founder and president of the world-renowned Mountain Trek program, now offers off-site interactive and eye-opening workshops — grounded in anthropological health science — to help professionals integrate lasting steps in reaching optimal wellness. With an inspiring, practical, and actionable message, Kirkland helps people see their own health through a fresh and practical lens.With half- and full-day interactive health workshops and keynote presentations — designed specifically for a corporate audience — held at your company's headquarters, Kirkland's life-changing interactive presentation can be tailored to meet a number of health issues: Fitness, Nutrition, De-Stressing, Sleep Hygiene, Physical and Digital Detoxification, Habit Formation, Mindfulness.His proven approach increases energy, productivity, and establishes long-lasting health habits. The program incorporates scientific anthropology blended with a distinctly mountain-centric approach to health. With 18 years' experience as president and founder of Mountain Trek's holistic health and vitality program, Kirkland brings more than 40 years of health-focused lifestyle expertise, with experience as a fitness instructor, lead hiking guide, wellness coach, Wilderness Park Manager, yoga instructor and meditation practitioner.Kirkland's off-site workshops for executives and employees have been hosted by leading organizations, such as Google, Young Presidents Organization of Western Canada, Fortis Gas, the CEO Network, European Entrepreneurs Organization, and more. Contact Kirkland Shave and Mountain Trek:Website: MountainTrek.com  https://mountaintrek.com/Instagram: @mountaintrek https://www.instagram.com/mountaintrek/Facebook: @mountaintrek https://www.facebook.com/mountaintrekInstagram: @mountaintrek  https://www.instagram.com/mountaintrekLinkedIn: Mountain-Trek  https://www.linkedin.com/company/mountain-trek/YouTube: YouTube.com/MountainTrek  https://www.youtube.com/mountaintrekKirkland Shave on LinkedIn: https://www.linkedin.com/in/kirkland-shave-66865b29/TripAdvisor: https://www.tripadvisor.com/Hotel_Review-g499116-d223075-Reviews-Mountain_Trek_Fitness_Retreat_Health_Spa-Ainsworth_Hot_Springs_Kootenay_Rockies_British.htmlAbout Dr. Kelly Tremblay, MSc PhD CEC-ACC:Dr. Trembly is committed to making aging better by innovating in the areas of health, tech, and education through leadership, research, and advocacy.She is a consultant, neuroscientist and clinical audiologist who has worked in healthcare, tech, and higher education for 25+ years. As a tenured professor, Dr. Tremblay's NIH-funded research shed light on how we can capitalize on the brain's plasticity to promote perceptual and behavior changes well into our later years. Her work in the areas of communication neuroscience, person-centred care, and digital health technology has been recognized with invitations to serve on many committees at the National Institutes of Health, the American Federation for Aging Research's National Scientific Advisory Council, Mitacs Canada, and the World Health Organization. She leads advocacy initiatives and serves on many boards, including the Hearing Loss Association of America, where she was a Board Trustee and Co-Founder and Chair of the Task Force for Accessible, Inclusive Employment.Because work and health are social determinants of quality of life and healthy aging, Dr. Tremblay also works with leaders in all sectors, as an ICF-certified executive coach, to promote healthy, accessible, multi-generational workplaces where people can flourish. She's certified by the International Coaching Federation and a Fellow of the McLean Institute of Coaching (an affiliate of Harvard Medical School), who loves helping people rewire and inspire!Contact Dr. Kelly Tremblay: Website: DrKellyTremblay.com  https://drkellytremblay.com/LinkedIn: Dr-Kelly_Tremblay  https://www.linkedin.com/in/dr-kelly-tremblay  Resources:Website: MountainTrek.com“Nature and human well-being: The olfactory pathway” Science Advances | May 2024 | Vol 10 Issue 20Parks Canada Health and WellnessShinrin-yoku“The Myth of Normal” by Gabor Mate“When Things Fall Apart” by Pema ChödrönLearn more about Dr. Laura on her website: https://drlaura.liveFor more resources, look into Dr. Laura's organizations: Canada Career CounsellingSynthesis Psychology

In many clinical contexts, substance use disorder is oftentreated separately from posttraumatic stress disorder. Yet, these conditions commonly co-occur and are reciprocally determinant, meaning that the outcomes of a course of treatment for either condition might depend upon treating theother. On this episode, Dr. Sudie Back talks about the importance of treating co-occurring PTSD and substance use disorder simultaneously, and the prolonged exposure treatment, COPE, she developed with her colleagues to manage both disorders. Dr. Sudie Back is a professor, and the director of the NIH-sponsored DART research training program, in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina. She is also a psychologist at the Ralph H. Johnson VA Hospital.

So far in 2025, the Trump administration has cut more than $1 billion in NIH grants. That includes a study on sickle cell disease, a blood disorder that affects roughly 100,000 people in the U.S. According to the CDC, 90% of them are Black. Ali Rogin speaks with Dr. Charity Oyedeji, a Duke University hematologist whose research grant was terminated, to learn more. PBS News is supported by - https://www.pbs.org/newshour/about/funders

So far in 2025, the Trump administration has cut more than $1 billion in NIH grants. That includes a study on sickle cell disease, a blood disorder that affects roughly 100,000 people in the U.S. According to the CDC, 90% of them are Black. Ali Rogin speaks with Dr. Charity Oyedeji, a Duke University hematologist whose research grant was terminated, to learn more. PBS News is supported by - https://www.pbs.org/newshour/about/funders

This episode features Paige Twenter, Assistant Editor at Becker's Hospital Review, sharing insights on two major developments in healthcare. She discusses the Joint Commission's sweeping reduction of hospital standards and the recent court rulings that reinstated billions in NIH research grant funding, signaling significant changes for academic medicine.

It's a uniquely challenging time for our nation's medical community. The Trump administration has set its sites on slashing federal funding for healthcare and research by tens of billions of dollars, which could be catastrophic for the NIH and CDC. Funding is tenuous to say the least. Then there's mounting political pressure to restrict access to care for low income families on Medicaid plus care for at-risk health groups like transgender Americans and immigrants. So how are healthcare leaders navigating these uncertain times? Today we're bringing you a live episode recorded at the Boston Globes Health Equity Summit in May. It's a conversation with Dr. Kevin Churchwell, CEO of Boston Children's Hospital. Dr. Churchwell and host Shirley Leung discuss how major changes at the federal level are impacting healthcare workers and patient care in Boston and beyond.

Dr. Paul Hanona and Dr. Arturo Loaiza-Bonilla discuss how to safely and smartly integrate AI into the clinical workflow and tap its potential to improve patient-centered care, drug development, and access to clinical trials. TRANSCRIPT Dr. Paul Hanona: Hello, I'm Dr. Paul Hanona, your guest host of the ASCO Daily News Podcast today. I am a medical oncologist as well as a content creator @DoctorDiscover, and I'm delighted to be joined today by Dr. Arturo Loaiza-Bonilla, the chief of hematology and oncology at St. Luke's University Health Network. Dr. Bonilla is also the co-founder and chief medical officer at Massive Bio, an AI-driven platform that matches patients with clinical trials and novel therapies. Dr. Loaiza-Bonilla will share his unique perspective on the potential of artificial intelligence to advance precision oncology, especially through clinical trials and research, and other key advancements in AI that are transforming the oncology field. Our full disclosures are available in the transcript of the episode. Dr. Bonilla, it's great to be speaking with you today. Thanks for being here. Dr. Arturo Loaiza-Bonilla: Oh, thank you so much, Dr. Hanona. Paul, it's always great to have a conversation. Looking forward to a great one today. Dr. Paul Hanona: Absolutely. Let's just jump right into it. Let's talk about the way that we see AI being embedded in our clinical workflow as oncologists. What are some practical ways to use AI? Dr. Arturo Loaiza-Bonilla: To me, responsible AI integration in oncology is one of those that's focused on one principle to me, which is clinical purpose is first, instead of the algorithm or whatever technology we're going to be using. If we look at the best models in the world, they're really irrelevant unless we really solve a real day-to-day challenge, either when we're talking to patients in the clinic or in the infusion chair or making decision support. Currently, what I'm doing the most is focusing on solutions that are saving us time to be more productive and spend more time with our patients. So, for example, we're using ambient AI for appropriate documentation in real time with our patients. We're leveraging certain tools to assess for potential admission or readmission of patients who have certain conditions as well. And it's all about combining the listening of physicians like ourselves who are end users, those who create those algorithms, data scientists, and patient advocates, and even regulators, before they even write any single line of code. I felt that on my own, you know, entrepreneurial aspects, but I think it's an ethos that we should all follow. And I think that AI shouldn't be just bolted on later. We always have to look at workflows and try to look, for example, at clinical trial matching, which is something I'm very passionate about. We need to make sure that first, it's easier to access for patients, that oncologists like myself can go into the interface and be able to pull the data in real time when you really need it, and you don't get all this fatigue alerts. To me, that's the responsible way of doing so. Those are like the opportunities, right? So, the challenge is how we can make this happen in a meaningful way – we're just not reacting to like a black box suggestion or something that we have no idea why it came up to be. So, in terms of success – and I can tell you probably two stories of things that we know we're seeing successful – we all work closely with radiation oncologists, right? So, there are now these tools, for example, of automated contouring in radiation oncology, and some of these solutions were brought up in different meetings, including the last ASCO meeting. But overall, we know that transformer-based segmentation tools; transformer is just the specific architecture of the machine learning algorithm that has been able to dramatically reduce the time for colleagues to spend allotting targets for radiation oncology. So, comparing the target versus the normal tissue, which sometimes it takes many hours, now we can optimize things over 60%, sometimes even in minutes. So, this is not just responsible, but it's also an efficiency win, it's a precision win, and we're using it to adapt even mid-course in response to tumor shrinkage. Another success that I think is relevant is, for example, on the clinical trial matching side. We've been working on that and, you know, I don't want to preach to the choir here, but having the ability for us to structure data in real time using these tools, being able to extract information on biomarkers, and then show that multi-agentic AI is superior to what we call zero-shot or just throwing it into ChatGPT or any other algorithm, but using the same tools but just fine-tuned to the point that we can be very efficient and actually reliable to the level of almost like a research coordinator, is not just theory. Now, it can change lives because we can get patients enrolled in clinical trials and be activated in different places wherever the patient may be. I know it's like a long answer on that, but, you know, as we talk about responsible AI, that's important. And in terms of what keeps me up at night on this: data drift and biases, right? So, imaging protocols, all these things change, the lab switch between different vendors, or a patient has issues with new emerging data points. And health systems serve vastly different populations. So, if our models are trained in one context and deployed in another, then the output can be really inaccurate. So, the idea is to become a collaborative approach where we can use federated learning and patient-centricity so we can be much more efficient in developing those models that account for all the populations, and any retraining that is used based on data can be diverse enough that it represents all of us and we can be treated in a very good, appropriate way. So, if a clinician doesn't understand why a recommendation is made, as you probably know, you probably don't trust it, and we shouldn't expect them to. So, I think this is the next wave of the future. We need to make sure that we account for all those things. Dr. Paul Hanona: Absolutely. And even the part about the clinical trials, I want to dive a little bit more into in a few questions. I just kind of wanted to make a quick comment. Like you said, some of the prevalent things that I see are the ambient scribes. It seems like that's really taken off in the last year, and it seems like it's improving at a pretty dramatic speed as well. I wonder how quickly that'll get adopted by the majority of physicians or practitioners in general throughout the country. And you also mentioned things with AI tools regarding helping regulators move things quicker, even the radiation oncologist, helping them in their workflow with contouring and what else they might have to do. And again, the clinical trials thing will be quite interesting to get into. The first question I had subsequent to that is just more so when you have large datasets. And this pertains to two things: the paper that you published recently regarding different ways to use AI in the space of oncology referred to drug development, the way that we look at how we design drugs, specifically anticancer drugs, is pretty cumbersome. The steps that you have to take to design something, to make sure that one chemical will fit into the right chemical or the structure of the molecule, that takes a lot of time to tinker with. What are your thoughts on AI tools to help accelerate drug development? Dr. Arturo Loaiza-Bonilla: Yes, that's the Holy Grail and something that I feel we should dedicate as much time and effort as possible because it relies on multimodality. It cannot be solved by just looking at patient histories. It cannot be solved by just looking at the tissue alone. It's combining all these different datasets and being able to understand the microenvironment, the patient condition and prior treatments, and how dynamic changes that we do through interventions and also exposome – the things that happen outside of the patient's own control – can be leveraged to determine like what's the best next step in terms of drugs. So, the ones that we heard the news the most is, for example, the Nobel Prize-winning [for Chemistry awarded to Demis Hassabis and John Jumper for] AlphaFold, an AI system that predicts protein structures right? So, we solved this very interesting concept of protein folding where, in the past, it would take the history of the known universe, basically – what's called the Levinthal's paradox – to be able to just predict on amino acid structure alone or the sequence alone, the way that three-dimensionally the proteins will fold. So, with that problem being solved and the Nobel Prize being won, the next step is, “Okay, now we know how this protein is there and just by sequence, how can we really understand any new drug that can be used as a candidate and leverage all the data that has been done for many years of testing against a specific protein or a specific gene or knockouts and what not?” So, this is the future of oncology and where we're probably seeing a lot of investments on that. The key challenge here is mostly working on the side of not just looking at pathology, but leveraging this digital pathology with whole slide imaging and identifying the microenvironment of that specific tissue. There's a number of efforts currently being done. One isn't just H&E, like hematoxylin and eosin, slides alone, but with whole imaging, now we can use expression profiles, spatial transcriptomics, and gene whole exome sequencing in the same space and use this transformer technology in a multimodality approach that we know already the slide or the pathology, but can we use that to understand, like, if I knock out this gene, how is the microenvironment going to change to see if an immunotherapy may work better, right? If we can make a microenvironment more reactive towards a cytotoxic T cell profile, for example. So, that is the way where we're really seeing the field moving forward, using multimodality for drug discovery. So, the FDA now seems to be very eager to support those initiatives, so that's of course welcome. And now the key thing is the investment to do this in a meaningful way so we can see those candidates that we're seeing from different companies now being leveraged for rare disease, for things that are going to be almost impossible to collect enough data, and make it efficient by using these algorithms that sometimes, just with multiple masking – basically, what they do is they mask all the features and force the algorithm to find solutions based on the specific inputs or prompts we're doing. So, I'm very excited about that, and I think we're going to be seeing that in the future. Dr. Paul Hanona: So, essentially, in a nutshell, we're saying we have the cancer, which is maybe a dandelion in a field of grass, and we want to see the grass that's surrounding the dandelion, which is the pathology slides. The problem is, to the human eye, it's almost impossible to look at every single piece of grass that's surrounding the dandelion. And so, with tools like AI, we can greatly accelerate our study of the microenvironment or the grass that's surrounding the dandelion and better tailor therapy, come up with therapy. Otherwise, like you said, to truly generate a drug, this would take years and years. We just don't have the throughput to get to answers like that unless we have something like AI to help us. Dr. Arturo Loaiza-Bonilla: Correct. Dr. Paul Hanona: And then, clinical trials. Now, this is an interesting conversation because if you ever look up our national guidelines as oncologists, there's always a mention of, if treatment fails, consider clinical trials. Or in the really aggressive cancers, sometimes you might just start out with clinical trials. You don't even give the standard first-line therapy because of how ineffective it is. There are a few issues with clinical trials that people might not be aware of, but the fact that the majority of patients who should be on clinical trials are never given the chance to be on clinical trials, whether that's because of proximity, right, they might live somewhere that's far from the institution, or for whatever reason, they don't qualify for the clinical trial, they don't meet the strict inclusion criteria.  But a reason you mentioned early on is that it's simply impossible for someone to be aware of every single clinical trial that's out there. And then even if you are aware of those clinical trials, to actually find the sites and put in the time could take hours. And so, how is AI going to revolutionize that? Because in my mind, it's not that we're inventing a new tool. Clinical trials have always been available. We just can't access them. So, if we have a tool that helps with access, wouldn't that be huge? Dr. Arturo Loaiza-Bonilla: Correct. And that has been one of my passions. And for those who know me and follow me and we've spoke about it in different settings, that's something that I think we can solve. This other paradox, which is the clinical trial enrollment paradox, right? We have tens of thousands of clinical trials available with millions of patients eager to learn about trials, but we don't enroll enough and many trials close to accrual because of lack of enrollment. It is completely paradoxical and it's because of that misalignment because patients don't know where to go for trials and sites don't know what patients they can help because they haven't reached their doors yet. So, the solution has to be patient-centric, right? We have to put the patient at the center of the equation. And that was precisely what we had been discussing during the ASCO meeting. There was an ASCO Education Session where we talked about digital prescreening hubs, where we, in a patient-centric manner, the same way we look for Uber, Instacart, any solution that you may think of that you want something that can be leveraged in real time, we can use these real-world data streams from the patient directly, from hospitals, from pathology labs, from genomics companies, to continuously screen patients who can match to the inclusion/exclusion criteria of unique trials. So, when the patient walks into the clinic, the system already knows if there's a trial and alerts the site proactively. The patient can actually also do decentralization. So, there's a number of decentralized clinical trial solutions that are using what I call the “click and mortar” approach, which is basically the patient is checking digitally and then goes to the site to activate. We can also have the click and mortar in the bidirectional way where the patient is engaged in person and then you give the solution like the ones that are being offered on things that we're doing at Massive Bio and beyond, which is having the patient to access all that information and then they make decisions and enroll when the time is right.  As I mentioned earlier, there is this concept drift where clinical trials open and close, the patient line of therapy changes, new approvals come in and out, and sites may not be available at a given time but may be later. So, having that real-time alerts using tools that are able already to extract data from summarization that we already have in different settings and doing this natural language ingestion, we can not only solve this issue with manual chart review, which is extremely cumbersome and takes forever and takes to a lot of one-time assessments with very high screen failures, to a real-time dynamic approach where the patient, as they get closer to that eligibility criteria, they get engaged. And those tools can be built to activate trials, audit trials, and make them better and accessible to patients. And something that we know is, for example, 91%-plus of Americans live close to either a pharmacy or an imaging center. So, imagine that we can potentially activate certain of those trials in those locations. So, there's a number of pharmacies, special pharmacies, Walgreens, and sometimes CVS trying to do some of those efforts. So, I think the sky's the limit in terms of us working together. And we've been talking with corporate groups, they're all interested in those efforts as well, to getting patients digitally enabled and then activate the same way we activate the NCTN network of the corporate groups, that are almost just-in-time. You can activate a trial the patient is eligible for and we get all these breakthroughs from the NIH and NCI, just activate it in my site within a week or so, as long as we have the understanding of the protocol. So, using clinical trial matching in a digitally enabled way and then activate in that same fashion, but not only for NCTN studies, but all the studies that we have available will be the key of the future through those prescreening hubs. So, I think now we're at this very important time where collaboration is the important part and having this silo-breaking approach with interoperability where we can leverage data from any data source and from any electronic medical records and whatnot is going to be essential for us to move forward because now we have the tools to do so with our phones, with our interests, and with the multiple clinical trials that are coming into the pipelines. Dr. Paul Hanona: I just want to point out that the way you described the process involves several variables that practitioners often don't think about. We don't realize the 15 steps that are happening in the background. But just as a clarifier, how much time is it taking now to get one patient enrolled on a clinical trial? Is it on the order of maybe 5 to 10 hours for one patient by the time the manual chart review happens, by the time the matching happens, the calls go out, the sign-up, all this? And how much time do you think a tool that could match those trials quicker and get you enrolled quicker could save? Would it be maybe an hour instead of 15 hours? What's your thought process on that? Dr. Arturo Loaiza-Bonilla: Yeah, exactly. So one is the matching, the other one is the enrollment, which, as you mentioned, is very important. So, it can take, from, as you said, probably between 4 days to sometimes 30 days. Sometimes that's how long it takes for all the things to be parsed out in terms of logistics and things that could be done now agentically. So, we can use agents to solve those different steps that may take multiple individuals. We can just do it as a supply chain approach where all those different steps can be done by a single agent in a simultaneous fashion and then we can get things much faster. With an AI-based solution using these frontier models and multi-agentic AI – and we presented some of this data in ASCO as well – you can do 5,000 patients in an hour, right? So, just enrolling is going to be between an hour and maximum enrollment, it could be 7 days for those 5,000 patients if it was done at scale in a multi-level approach where we have all the trials available. Dr. Paul Hanona: No, definitely a very exciting aspect of our future as oncologists. It's one thing to have really neat, novel mechanisms of treatment, but what good is it if we can't actually get it to people who need it? I'm very much looking for the future of that.  One of the last questions I want to ask you is another prevalent way that people use AI is just simply looking up questions, right? So, traditionally, the workflow for oncologists is maybe going on national guidelines and looking up the stage of the cancer and seeing what treatments are available and then referencing the papers and looking at who was included, who wasn't included, the side effects to be aware of, and sort of coming up with a decision as to how to treat a cancer patient. But now, just in the last few years, we've had several tools become available that make getting questions easier, make getting answers easier, whether that's something like OpenAI's tools or Perplexity or Doximity or OpenEvidence or even ASCO has a Guidelines Assistant as well that is drawing from their own guidelines as to how to treat different cancers. Do you see these replacing traditional sources? Do you see them saving us a lot more time so that we can be more productive in clinic? What do you think is the role that they're going to play with patient care? Dr. Arturo Loaiza-Bonilla: Such a relevant question, particularly at this time, because these AI-enabled query tools, they're coming left and right and becoming increasingly common in our daily workflows and things that we're doing. So, traditionally, when we go and we look for national guidelines, we try to understand the context ourselves and then we make treatment decisions accordingly. But that is a lot of a process that now AI is helping us to solve. So, at face value, it seems like an efficiency win, but in many cases, I personally evaluate platforms as the chief of hem/onc at St. Luke's and also having led the digital engagement things through Massive Bio and trying to put things together, I can tell you this: not all tools are created equal. In cancer care, each data point can mean the difference between cure and progression, so we cannot really take a lot of shortcuts in this case or have unverified output. So, the tools are helpful, but it has to be grounded in truth, in trusted data sources, and they need to be continuously updated with, like, ASCO and NCCN and others. So, the reason why the ASCO Guidelines Assistant, for instance, works is because it builds on all these recommendations, is assessed by end users like ourselves. So, that kind of verification is critical, right? We're entering a phase where even the source material may be AI-generated. So, the role of human expert validation is really actually more important, not less important. You know, generalist LLMs, even when fine-tuned, they may not be enough. You can pull a few API calls from PubMed, etc., but what we need now is specialized, context-aware, agentic tools that can interpret multimodal and real-time clinical inputs. So, something that we are continuing to check on and very relevant to have entities and bodies like ASCO looking into this so they can help us to be really efficient and really help our patients. Dr. Paul Hanona: Dr. Bonilla, what do you want to leave the listener with in terms of the future direction of AI, things that we should be cautious about, and things that we should be optimistic about? Dr. Arturo Loaiza-Bonilla: Looking 5 years ahead, I think there's enormous promise. As you know, I'm an AI enthusiast, but always, there's a few priorities that I think – 3 of them, I think – we need to tackle head-on. First is algorithmic equity. So, most AI tools today are trained on data from academic medical centers but not necessarily from community practices or underrepresented populations, particularly when you're looking at radiology, pathology, and what not. So, those blind spots, they need to be filled, and we can eliminate a lot of disparities in cancer care. So, those frameworks to incentivize while keeping the data sharing using federated models and things that we can optimize is key. The second one is the governance on the lifecycle. So, you know, AI is not really static. So, unlike a drug that is approved and it just, you know, works always, AI changes. So, we need to make sure that we have tools that are able to retrain and recall when things degrade or models drift. So, we need to use up-to-date AI for clinical practice, so we are going to be in constant revalidation and make it really easy to do. And lastly, the human-AI interface. You know, clinicians don't need more noise or we don't need more black boxes. We need decision support that is clear, that we can interpret, and that is actionable. “Why are you using this? Why did we choose this drug? Why this dose? Why now?” So, all these things are going to help us and that allows us to trace evidence with a single click. So, I always call it back to the Moravec's paradox where we say, you know, evolution gave us so much energy to discern in the sensory-neural and dexterity. That's what we're going to be taking care of patients. We can use AI to really be a force to help us to be better clinicians and not to really replace us. So, if we get this right and we decide for transparency with trust, inclusion, etc., it will never replace any of our work, which is so important, as much as we want, we can actually take care of patients and be personalized, timely, and equitable. So, all those things are what get me excited every single day about these conversations on AI. Dr. Paul Hanona: All great thoughts, Dr. Bonilla. I'm very excited to see how this field evolves. I'm excited to see how oncologists really come to this field. I think with technology, there's always a bit of a lag in adopting it, but I think if we jump on board and grow with it, we can do amazing things for the field of oncology in general. Thank you for the advancements that you've made in your own career in the field of AI and oncology and just ultimately with the hopeful outcomes of improving patient care, especially cancer patients. Dr. Arturo Loaiza-Bonilla: Thank you so much, Dr. Hanona. Dr. Paul Hanona: Thanks to our listeners for your time today. If you value the insights that you hear on ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Arturo Loaiza-Bonilla @DrBonillaOnc Dr. Paul Hanona @DoctorDiscover on YouTube Follow ASCO on social media:      @ASCO on Twitter      ASCO on Facebook      ASCO on LinkedIn    ASCO on BlueSky Disclosures: Paul Hanona: No relationships to disclose. Dr. Arturo-Loaiza-Bonilla: Leadership: Massive Bio Stock & Other Ownership Interests: Massive Bio Consulting or Advisory Role: Massive Bio, Bayer, PSI, BrightInsight, CardinalHealth, Pfizer, AstraZeneca, Medscape Speakers' Bureau: Guardant Health, Ipsen, AstraZeneca/Daiichi Sankyo, Natera

Življenjska zgodba Mehmedalije Alića je zapisana v njegovi avtobiografiji “Nihče” in upodobljena v celovečernem filmu “Rudar”. Skoraj še kot otrok je prišel rudarit v Zasavje, bil izbrisan, v Srebrenici sta bila ubita dva njegova brata, odkril je množično grobišče v Hudi Jami. Po upokojitvi zadnje desetletje živi v bližini Tuzle ter išče svoj mir in drugačno, manj stresno življenje. Z nami je obiskal svojo rojstno vas Grujičići in širše območje Srebrenice, ki ga spominja na čudovito otroštvo in tragično realnost. Mehmedalija Alić razmišlja o miru, solidarnosti, odpuščanju … Zakaj se je vredno boriti in živeti, zakaj ima igrišče, ki ga je zgradil v svoji vasi, smisel, četudi se na njem igra samo en otrok?Razpoke miru: Baljvine, vas, kjer Bošnjaki in Srbi živijo v sožitju Petrinja na ruševinah vojne in potresa gradi novo prihodnost Srbi na Hrvaškem se borijo za reko v Bosni Vse, kar je pozitivnega v Srebrenici, nekoga moti Sarajevski razmisleki Z bojem za okolje proti naučeni nemoči Mustafa Nukić – od begunskega naselja v Ljubljani do idola navijačev Olimpije  

When it comes to medical science, there's never been a better time to be alive than now… other than maybe a few months ago before the new Trump administration. Americans today are living longer than ever before, and that's owed in no small part to the National Institutes of Health—a government organization that has been responsible for some of the most significant biomedical advancements in the history of healthcare. Unfortunately, the Trump administration just virtually annihilated the NIH, and sentient gob of clay and anti-vax charlatan RFK Jr. is now in charge of the future of American health. To figure how how to navigate this insane dichotomy of medical potential and squandered medical possibility, Adam speaks with Dr. Eric Topol, a cardiologist and scientist, and director of the Scripps Research Translational Institute. Dr. Topol's book, Super Agers: An Evidence-Based Approach to Longevity, explores the cutting edge advancements in living longer, healthier lives—advancements which are now in jeopardy. Find Dr. Topol's book at factuallypod.com/books--SUPPORT THE SHOW ON PATREON: https://www.patreon.com/adamconoverSEE ADAM ON TOUR: https://www.adamconover.net/tourdates/SUBSCRIBE to and RATE Factually! on:» Apple Podcasts: https://podcasts.apple.com/us/podcast/factually-with-adam-conover/id1463460577» Spotify: https://open.spotify.com/show/0fK8WJw4ffMc2NWydBlDyJAbout Headgum: Headgum is an LA & NY-based podcast network creating premium podcasts with the funniest, most engaging voices in comedy to achieve one goal: Making our audience and ourselves laugh. Listen to our shows at https://www.headgum.com.» SUBSCRIBE to Headgum: https://www.youtube.com/c/HeadGum?sub_confirmation=1» FOLLOW us on Twitter: http://twitter.com/headgum» FOLLOW us on Instagram: https://instagram.com/headgum/» FOLLOW us on TikTok: https://www.tiktok.com/@headgum» Advertise on Factually! via Gumball.fmSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What to know about the National Institutes of Health's major announcement that changes everything when it comes to animal testing in research. If you want NIH funding and use animals in your models and tests, your grant application will not be welcome. PETA's Dr. Emily Trunnell talks to Emil Guillermo about the significance of this change and what more needs to be done to make an even bigger difference to animals and science. Go to PETA.org for more details  The PETA Podcast PETA, the world's largest animal rights organization, is 9 million strong.  Hosted by Emil Guillermo. Contact us at PETA.org Music provided by CarbonWorks. Go to Apple podcasts and subscribe. Contact and follow host Emil Guillermo on X@emilamok Get this podcast at www.YouTube.com/@emilamok1 Or at www.amok.com Please subscribe, rate, and review wherever you get your podcasts. Thanks for listening to THE PETA PODCAST!  Reprised, July 9, 2025  ©PETA, Emil Guillermo 2023-25        

In this episode I'm joined by Dr. Maria Sophocles to break the silence around painful sex, vaginal atrophy, menopause, and the damaging scripts of ‘duty sex'. Dr. Sophocles shares:Why so many women endure painful sex silentlyThe difference between vaginal atrophy, vulvodynia, and other causes of painHow treatments like vaginal estrogen, lubricants, and dilators can helpWhy sexual pain should never define your worth as a partnerThe importance of communication with doctors and partnersHer upcoming documentary HOT! exploring midlife women's sexualityHer personal definition of sex: joy, curiosity, and humorThis episode is a must-listen for any woman wanting to understand her body, break free from shame, and embrace a sex life defined by her own needs and desires.Timestamps:00:00 – Intro & Guest Welcome02:10 – The Reality of Painful Sex Globally05:50 – Dr. Maria Sophocles' Work & TED Talk Impact09:20 – Mercy Sex, Duty Sex, and The Bedroom Gap14:00 – Why Women Feel Obliged to Endure Pain17:50 – Common Causes of Painful Sex in Midlife21:40 – Treatments: Vaginal Estrogen, Lubricants, Dilators26:10 – How To Talk To Your Doctor About Sex31:30 – Communicating With Your Partner About Pain & Pleasure38:00 – The Importance of Sexual Check-Ins43:20 – Dr. Sophocles' Upcoming Documentary HOT!47:10 – Her Personal Definition of Sex49:00 – Closing Thoughts & Next StepsKaren Bigman, a Sexual Health Alliance Certified Sex Educator, Life, and Menopause Coach, tackles the often-taboo subject of sexuality with a straightforward and candid approach. We explore the intricacies of sex during perimenopause, post-menopause, and andropause, offering insights and support for all those experiencing these transformative phases.This podcast is not intended to give medical advice. Karen Bigman is not a medical professional. For any medical questions or issues, please visit your licensed medical provider.Looking for some fresh perspective on sex in midlife? You can find me here:Email: karen@taboototruth.comWebsite: https://www.taboototruth.com/Instagram: https://www.instagram.com/taboototruthYouTube: https://www.youtube.com/@taboototruthpodcastAbout the Guest:Dr. Maria Sophocles has been a leader in women's healthcare for nearly 30 years, specializing in menopause management and female sexual health. She founded Women's Healthcare of Princeton, a progressive gynecology practice, and has been a visiting professor and NIH researcher in Switzerland. A board-certified ob/gyn and Menopause Society Certified Practitioner, she has pioneered innovative treatments, including CO2 laser therapy for vaginal atrophy. She serves as CMO of EMBR Labs, Director of Women's Health Services for Curia Health, and is an advocate for women's health policy. Dr. Sophocles is also an author, TEDWomen2023 speaker, and frequent media contributor on women's health topics.Connect with Dr. Maria Sophocles:Website: https://mariasophoclesmd.comInstagram:

On this explosive Independence Day episode of We Want Them Infected, hosts Dr. Jonathan Howard and Wendy Orent unravel a sobering transformation in U.S. public health. With agencies like the ACIP and NIH now steered by politically motivated leaders like RFK Jr., Vinay Prasad, and Jay Bhattacharya, science is taking a backseat to ideology. They dive deep into the disastrous ACIP meeting stacked with anti-vaccine appointees, the chilling disinformation from NIH and FDA leadership, and the real-world impact—from cancer patients being denied life-saving clinical trials to families unable to access COVID vaccines. This episode is a powerful wake-up call for anyone concerned about science, truth, and the future of medicine. Connect with us further on https://sciencebasedmedicine.org/author/jonathanhoward/  The Fine Print The content presented in the "We Want Them Infected" Podcast and associated book is intended for informational and educational purposes only.    The views and opinions expressed by the speakers, hosts, and guests on the podcast do not necessarily reflect the views of the creators, producers, or distributors. The information provided in this podcast should not be considered as a substitute for professional medical, scientific, or legal advice. Listeners and readers are encouraged to consult with relevant experts and authorities for specific guidance and information.   The creators of the podcast and book have made reasonable efforts to ensure that the information provided is accurate and up to date. However, as the field of medical science and the understanding of the COVID-19 pandemic continue to evolve, there may be new developments and insights that are not covered in this content.   The creators are not responsible for any errors or omissions in the content or for any actions taken based on the information provided. They disclaim any liability for any loss, injury, or damage incurred by individuals who rely on the content.   Listeners and readers are urged to use their judgment and conduct their own research when interpreting the information presented in the "We Want Them Infected" podcast and book. It is essential to stay informed about the latest updates, guidelines, and recommendations related to COVID-19 and vaccination from reputable sources, such as government health agencies and medical professionals. By accessing and using the content, you acknowledge and accept the terms of this disclaimer.   Please consult with appropriate experts and authorities for specific guidance on matters related to health, science, and the COVID-19 pandemic.  

TWiV covers FDA Director overriding scientists on COVID shots, NIH funded science must now be free to read instantly, Trump cuts subscriptions to Springer Nature journals, UK and Gates make up for US money withdrawn from GAVI, US defunding USAID could lead to 14 million deaths by 2030, then reviews research on how host IL1 genetics regulates Epstein-Barr virus reactivation and long COVID, and enhanced antiviral capacity of bat innate immunity. Hosts: Vincent Racaniello, Alan Dove, and Rich Condit Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV FDA official overrides scientists on COVID shots (NYTimes) NIH funded science must be immediately open access (Nature) Trump cuts journal subscriptions for NIH (Science) Donors make up GAVI US shortfall (Reuters) USAID defunding will lead to 14 million deaths (CIDRAP) SARS-CoV-2, IL1, Epstein-Barr virus and long COVID (Cell Rep) Bat innate immunity (Nat Comm) Letters read on TWiV 1233 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Rich – Unraveling Mendel's final mysteries: A genomic retelling of pea genetics (Thanks, Kathy!) (Original article) Alan – Winners of Nature's 2025 “Scientist at Work” photo competition Vincent – Signs of AI-generated text found in 14% of biomedical abstracts last year Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

In this episode of BioTalk, Rich Bendis welcomes Dr. Helen Sabzevari, President and CEO of Precigen, to discuss the company's cutting-edge science in gene and cell therapy. Dr. Sabzevari shares how Precigen's unique AdenoVerse® platform has powered the development of PRGN-2012, a potential first-in-class therapeutic currently under FDA priority review for the treatment of adults with recurrent respiratory papillomatosis (RRP), a rare and devastating disease. She also highlights advances across Precigen's broader pipeline in immuno-oncology and autoimmune disease and reflects on how Maryland's BioHealth Capital Region has supported the company's innovation and growth.   Editing and post-production work for this episode was provided by The Podcast Consultant.   Dr. Helen Sabzevari is the President and CEO of Precigen, Inc., and a leading expert in immunotherapy-based therapeutics. She previously served in executive roles at Compass Therapeutics and Merck KGaA/EMD Serono, where she advanced numerous immuno-oncology programs. Dr. Sabzevari began her career at the National Cancer Institute and has been widely recognized for her leadership and scientific contributions, including honors from NIH, SITC, and Forbes.

Normal pressure hydrocephalus (NPH) is a clinical syndrome characterized by the triad of gait apraxia, cognitive impairment, and bladder dysfunction in the radiographic context of ventriculomegaly and normal intracranial pressure. Accurate diagnosis requires consideration of clinical and imaging signs, complemented by tests to exclude common mimics. In this episode, Lyell Jones, MD, FAAN speaks with Abhay R. Moghekar, MBBS, author of the article “Clinical Features and Diagnosis of Normal Pressure Hydrocephalus” in the Continuum® June 2025 Disorders of CSF Dynamics issue. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Moghekar is an associate professor of neurology at Johns Hopkins University School of Medicine in Baltimore, Maryland. Additional Resources Read the article: Clinical Features and Diagnosis of Normal Pressure Hydrocephalus Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today I'm interviewing Dr Abhay Moghekar, who recently authored an article on the clinical features and diagnosis of normal pressure hydrocephalus for our first-ever issue of Continuum dedicated to disorders of CSF dynamics. Dr Moghekar is an associate professor of neurology and the research director of the Cerebrospinal Fluid Center at Johns Hopkins University in Baltimore, Maryland. Dr Moghekar, welcome, and thank you for joining us today. Why don't you introduce yourself to our listeners? Dr Moghekar: Thank you, Dr Jones. I'm Abhay Moghekar. I'm a neurologist at Hopkins, and I specialize in seeing patients with CSF disorders, of which normal pressure hydrocephalus happens to be the most common. Dr Jones: And let's get right to it. I think most of our listeners who are neurologists in practice have encountered normal pressure hydrocephalus, or NPH; and it's a challenging disorder for all the reasons that you outline in your really outstanding article. If you were going to think of one single most important message to our listeners about recognizing patients with NPH, what would that be? Dr Moghekar: I think I would say there are two important messages. One is that the triad is not sufficient to make the diagnosis, and the triad is not necessary to make the diagnosis. You know these three elements of the triad: cognitive problems, gait problems, bladder control problems are so common in the elderly that if you pick 10 people out in the community that have this triad, it's unlikely that even one of them has true NPH. On the other hand, you don't need all three elements of the triad to make the diagnosis because the order of symptoms matters. Often patients develop gait dysfunction first, then cognitive dysfunction, and then urinary incontinence. If you wait for all three elements of the triad to be present, it may be too late to offer them any clear benefit. And hence, you know, it's neither sufficient nor necessary to make the diagnosis. Dr Jones: That's a really great point. I think most of our listeners are familiar with the fact that, you know, we're taught these classic triads or pentads or whatever, and they're rarely all present. In a way, it's maybe a useful prompt, but it could be distracting or misleading, even in a way, in terms of recognizing the patient. So what clues do you use, Dr Moghekar, to really think that a patient may have NPH? Dr Moghekar: So, there are two important aspects about gait dysfunction. Say somebody comes in with all three elements of the triad. You want to know two things. Which came first? If gate impairment precedes cognitive impairment, it's still very likely that NPH is in the differential. And of the two, which are more- relatively more affected? So, if somebody has very severe dementia and they have a little bit of gait problems, NPH is not as likely. So, is gait affected earlier than cognitive dysfunction, and is it affected to a more severe degree than cognitive dysfunction? And those two things clue me in to the possibility of NPH. You still obviously need to get imaging to make sure that they have large ventricles. One of the problems with imaging is large ventricles are present in so many different patients. Normal aging causes large ventricles. Obviously, many neurodegenerative disorders because of cerebral atrophy will cause large ventricles. And there's an often-used metric called as the events index, which is the ratio of the bitemporal horns- of the frontal horns of the lateral ventricles compared to the maximum diameter of the skull at that level. And if that ratio is more than 0.3, it's often used as a de facto measure of ventriculomegaly. What we've increasingly realized is that this ratio changes with age. And there's an excellent study that used the ADNI database that looked at how this ratio changes by age and sex. So, in fact, we now know that an 85-year-old woman who has an events index of 0.37 which would be considered ventriculomegaly is actually normal for age and sex. So, we need to start adopting these more modern age- and sex-appropriate age cutoffs of ventriculomegaly so as not to overcall everybody with big ventricles as having possible NPH. Dr Jones: That's very helpful. And I do want to come back to this challenge that we've seen in our field of overdiagnosis and underdiagnosis. But I think most of us are familiar with the concept of how hydrocephalus could cause neurologic deficits. But what's the latest on the mechanism of NPH? Why do some patients get this and others don't? Dr Moghekar: Very good question. I don't think we know for sure. And it for a long time we thought it was a plumbing issue. Right? And that's why shunts work. People thought it was impaired CSF absorption, but multiple studies have shown that not to be true. It's likely a combination of impaired cerebral blood flow, biomechanical factors like compliance, and even congenital factors that play a role in the pathogenesis of NPH. And yes, while putting in shunts likely drains CSF, putting in a shunt also definitely changes the compliance of the brain and affects blood flow to the subcortical regions of the brain. So, there are likely multiple mechanisms by which shunts benefit, and hence it's very likely that there's no single explanation for the pathogenesis of NPH. Dr Jones: We explored this in a recent Continuum issue on dementia. Many patients who have cognitive impairment have co-pathologies, multiple different causes. I was interested to read in your article about the genetic risk profile for NPH. It's not something I'd ever really considered in a disorder that is predominantly seen in older patients. Tell us a little more about those genetic risks. Dr Moghekar: Yeah, everyone is aware of the role genetics plays in congenital hydrocephalus, but until recently we were not aware that certain genetic factors may also be relevant to adult-onset normal pressure hydrocephalus. We've suspected this for a long time because nearly half of our patients who come to us to see us in clinic with NPH have head circumferences that are more than 90th percentile for height. And you know, that clearly indicates that this started shortly at the time after birth or soon afterwards. So, we've suspected for a long time that genetic factors play a role, but for a long time there were not enough large studies or well-conducted studies. But recently studies out of Japan and the US have shown mutations in genes like CF43 and CWH43 are disproportionately increased in patients with NPH. So, we are discovering increasingly that there are genetic factors that underlie even adult onset in patients. There are many more waiting to be discovered. Dr Jones: Really fascinating. And obviously getting more insight into the risk and mechanisms would be helpful in identifying these patients potentially earlier. And another thing that I learned in your article that I thought was really interesting, and maybe you can tell us more about it, is the association between normal pressure hydrocephalus and the observation of cervical spinal stenosis, many of whom require decompression. What's behind that association, do you think? Dr Moghekar: That's a very interesting study that was actually done at your institution, at Mayo Clinic, that showed this association. You know, as we all get older, you know, the incidence of cervical stenosis due to osteoarthritis goes up, but the incidence of significant, clinically significant cervical stenosis in the NPH population was much higher than what we would have expected. Whether this is merely an association in a vulnerable population or is it actually causal is not known and will need further study. Dr Jones: It's interesting to speculate, does that stenosis affect the flow of CSF and somehow predispose to a- again, maybe a partial degree for some patients? Dr Moghekar: Yeah, which goes back to the possible hydrodynamic theory of normal pressure hydrocephalus; you know, if it's obstructing normal CSF flow, you know, are the hydrodynamics affected in the brain that in turn could lead to the development of hydrocephalus. Dr Jones: One of the things I really enjoyed about your article, Abhay, was the very strong clinical focus, right? We can't just take an isolated biomarker or radiographic feature and rely on that, right? We really do need to have clinical suspicion, clinical judgment. And I think most of our listeners who've been in practice are familiar with the use and the importance of the large-volume lumbar puncture to determine who may have, and by exclusion not have, NPH, and then who might respond to CSF diversion. And I think those of us who have been in this situation are also familiar with the scenario where you think someone may have NPH and you do a large-volume lumbar puncture and they feel better, but you can't objectively see a difference. How do you make that test useful and objective in your practice? What do you do? Dr Moghekar: Yeah, it's a huge challenge in getting this objective assessment done carefully because you have to remember, you know, subconsciously you're telling the patients, I think you have NPH. I'm going to do this spinal tap, and if you walk better afterwards, you're going to get a shunt and you're going to be cured. And you can imagine the huge placebo response that can elicit in our subjects. So, we always like to see, definitely, did the patient subjectively feel better? Because yes, that's an important metric to consider because we want them to feel better. But we also wanted to be grounded in objective truths. And for that, we need to do different tests of speed, balance and endurance. Not everyone has the resources to do this, but I think it's important to test different domains. Just like for cognition, you know, we just don't test memory, right? We test executive function, language, visuospatial function. Similarly, walking is not just walking, right? It's gait speed, it's balance, and it's endurance. So, you need to ideally test at least most of these different domains for gait and you need to have some kind of clear criteria as to how are you going to define improvement. You know, is a 5% improvement, is a 10% improvement in gait, enough? Is 20%? Where is that cutoff? And as a field, we've not done a great job of coming up with standardized criteria for this. And it varies currently, the practice varies quite significantly from center to center at the current time. Dr Jones: So, one of the nice things you had in your article was helpful tips to be objective if you're in a lower-resource setting. For you, this isn't a common scenario that someone encounters in their practice as opposed to a center that maybe does a large volume of these. What are some relatively straightforward objective measures that a neurologist or someone else might use to determine if someone is improving after a large-volume LP? Dr Moghekar: Yeah, excellent question, Dr Jones, and very practically relevant too. So, you need to at least assess two of the domains that are most affected. One is speed and one is balance. You know, these patients fall ultimately, right, if you don't treat them correctly. In terms of speed, there are two very simple tests that anybody can do within a couple of minutes. One is the timed “up-and-go” test. It's a test that's even recommended by the CDC. It correlates very well with faults and disability and it can be done in any clinic. You just need about ten feet of space and a chair and a stopwatch, and it takes about a minute or slightly more to do that test. And there are objective age-associated norms for the timed up-and-go test, so it's easy to know if your patient is normal or not. The same thing goes for the 10-meter walk test. You do need a slightly longer walkway, but it's a fairly easy and well-standardized test. So, you can do one of those two; you don't need to do both of them. And for balance, you can do the 30-second “sit-to-stand”; and it's literally, again, 30 seconds. You need a chair, and you need somebody to watch the patient and see how many times they can sit up and stand up from a seated position. Then again, good normative data for that. If you want to be a little more sophisticated, you can do the 4-stage balance test. So, I think these are tests that don't add too much time to your daily assessment and can be done with even trained medical assistants in any clinic. And you don't need a trained physical therapist to do these assessments. Dr Jones: Very practical. And again, something that is pretty easily deployed, something we do before and then after the LP. I did see you mentioned in your article the dual timed up-and-go test where it's a simultaneous gait and executive function test. And I've got to be honest with you, Dr Moghekar, I was a little worried if I would pass that test, but that may be beyond the scope of our time today. Actually, how do you do that? How do you do the simultaneous cognitive assessment? Dr Moghekar: So, we asked them to count back from 100, subtracting 3. And we do it particularly in patients who are mildly impaired right? So, if they're already walking really good, but then you give them a cognitive stressor, you know, that will slow them down. So, we reserve it for patients who are high-performing. Dr Jones: That's fantastic. I'm probably aging myself a little here. I have noticed in my career, a little bit of a pendulum swing in terms of the recognition or acceptance of the prevalence of normal pressure hydrocephalus. I recall when I was a resident, many, many people that we saw in clinic had normal pressure hydrocephalus. Then it seemed for a while that it really faded into the background and was much less discussed and much less recognized and diagnosed, and less treated. And now that pendulum seems to have swung back the other way. What's behind that from your perspective? Dr Moghekar: It's an interesting backstory to all of this. When the first article about NPH was published in the Newman Journal of Medicine, it was actually a combined article with both neurologists and neurosurgeons on it. They did describe it as a treatable dementia. And what that did is it opened up the floodgates so that everybody with any kind of dementia started getting shunts left, right, and center. And back then, shunts were not programmable. There were no antibiotic impregnated catheters. So, the incidence of subdural hematomas and shunt-related infections was very high. In fact, one of our esteemed neurologists back then, Houston Merritt, wrote a scathing editorial that Victor and Adam should lose their professorships for writing such an article because the outcomes of these patients were so bad. So, for a very long period of time, neurologists stopped seeing these patients and stopped believing in NPH as a separate entity. And it became the domain of neurosurgeons for over two or three decades, until more recently when randomized trials started being done early on out of Europe. And now there's a big NIH study going on in the US, and these studies showed, in fact, that NPH exists as a true, distinct entity. And finally, neurologists have started getting more interested in the science and understanding the pathophysiology and taking care of these patients compared to the past. Dr Jones: That's really helpful context. And I guess that maybe isn't rare when you have a disorder that doesn't have a simple, straightforward biomarker and is complex in terms of the tests you need to do to support the diagnosis, and the treatment itself is somewhat invasive. So, when you talk to your patients, Dr Moghekar, and you've established the diagnosis and have recommended them for CSF diversion, what do you tell them? And the reason I ask is that you mentioned before we started recording, you had a patient who had a shunt placed and responded well, but continued to respond over time. Tell us a little bit more about what our patients can expect if they do have CSF diversion? Dr Moghekar: When we do the spinal tap and they meet our criteria for improvement and they go on to have a shunt, we tell them that we expect gait improvement definitely, but cognitive improvement may not happen in everyone depending on what time, you know, they showed up for their assessment and intervention. But we definitely expect gait improvement. And we tell them that the minimum gait improvement we can expect is the same degree of improvement they had after their large-volume lumbar puncture, but it can be even more. And as the brain remodels, as the hydrodynamics adapt to these shunts… so, we have patients who continue to improve one year, two years, and even three years into the course of the intervention. So, we're, you know, hopeful. At the same time, we want to be realistic. This is the same population that's at risk for developing neurodegenerative disorders related to aging. So not a small fraction of our patients will also have Alzheimer's disease, for example, or go on to develop Lewy body dementia. And it's the role of the neurologist to pick up on these comorbid conditions. And that's why it's important for us to keep following these patients and not leave them just to the neurosurgeon to follow up. Dr Jones: And what a great note to end on, Dr Moghekar. And again, I want to thank you for joining us, and thank you for such a wonderful discussion and such a fantastic article on the clinical diagnosis of normal pressure hydrocephalus. I learned a lot reading the article, and I learned a lot more today just in the conversation with you. So, thank you for being with us. Dr Moghekar: Happy to do that, Dr Jones. It was a pleasure. Dr Jones: Again, we've been speaking with Dr Abhay Moghekar, author of a wonderful article on the clinical features and diagnosis of NPH in Continuum's first-ever issue dedicated to disorders of CSF dynamics. Please check it out. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

North Korean IT Worker Fraud Scheme:The U.S. Department of Justice uncovered a covert North Korean operation involving IT workers fraudulently securing remote jobs at over 100 American tech companies using stolen or fake identities. These workers operated within U.S.-based "laptop farms" and created shell companies to obscure over $5 million in illicit earnings. Funds were funneled to the North Korean government, supporting weapons development. The scheme also involved data theft, including sensitive source code from a U.S. defense contractor.Android 16 Anti-Surveillance Feature:Android 16 introduces a “network notification” security upgrade that alerts users when their device connects to suspicious or unencrypted cell networks. It specifically guards against fake cell towers, such as stingray devices, by warning users about network requests for identifiers or lack of encryption, enhancing protection from mobile surveillance and forced downgrades to insecure protocols.Critical Printer Vulnerabilities:Rapid7 researchers identified eight major vulnerabilities affecting printers from Brother, Ricoh, Toshiba, Konica Minolta, and Fujifilm. The most critical flaw (CVE-2024-51978) lets remote attackers bypass admin authentication by exploiting a companion vulnerability (CVE-2024-51977) that reveals the printer's serial number—used to generate default admin credentials. This enables unauthorized reconfiguration and access to stored sensitive documents.Microsoft Authenticator Password Phase-Out:Microsoft will remove password autofill and access features from its Authenticator app starting July 2025. The move supports a transition to passwordless sign-ins using biometrics (e.g., facial recognition, fingerprints) and passkeys, aligning with industry shifts toward stronger, phishing-resistant authentication methods.NIH Open-Access Research Mandate:A new U.S. NIH policy mandates that all taxpayer-funded research be freely accessible upon publication. This accelerates an open-access directive initiated under Biden and implemented during the Trump administration. The policy enhances public access to scientific discoveries and may enable AI tools to help interpret complex studies for broader audiences.Pro-Scottish Independence Account Shutdowns:On June 12, multiple X (formerly Twitter) accounts advocating for Scottish independence vanished in sync with an Israeli cyber strike on Iran. The timing and scope of internet outages in Iran imply that the accounts were likely Iranian-run disinformation tools designed to destabilize the UK under the guise of grassroots political advocacy.Facebook Camera Roll Upload Concerns:Facebook is asking users to opt in to uploading unshared photos from their camera roll to Meta's servers to enable AI-generated content (e.g., collages). While Meta states that content remains private and isn't used for advertising, users must accept AI Terms that permit facial recognition, retention of loosely defined personal data, and potential human review—raising serious privacy concerns over intimate, unshared images.Meta's AI Superlab Push:Meta has launched “Meta Superintelligence Labs” and is heavily investing in top AI talent, reportedly offering compensation packages in the $10 million range. This underscores Meta's ambition to lead in high-end AI development, marking its entry into the elite tier of the global “AI arms race” beyond consumer-facing chatbots.

This week we've got loads of news and loadsa money!North Korean IT workers secretly landed remote jobs at over 100 U.S. tech companies, funneling millions to fund Kim Jong Un's weapons program.  The operation ran for years undetected—until the FBI knocked on the wrong contractor's door.Android 16 is getting a stealthy new feature that alerts users when their phone connects to suspicious cell towers.Think your phone isn't being watched?  Your operating system might soon say otherwise.A massive printer vulnerability affects nearly 700 Brother models and devices from other major brands.Hackers can bypass admin passwords with nothing but a serial number—guess what's sitting unsecured in your office?Microsoft is phasing out passwords in its Authenticator app, starting a full pivot to biometrics and passkeys.  You've got until August 2025 before your autofill feature goes dark.The NIH now requires that all taxpayer-funded research be freely available the moment it's published.  In a surprise move, the Trump administration just fast-tracked open science—seriously.  What?Dozens of pro-Scottish independence X accounts suddenly went dark after Israeli strikes crippled Iranian cyber infrastructure.  Turns out, your favorite “local activist” might have been powered by Tehran.Facebook wants permission to scan your unposted camera roll photos using Meta AI for creative suggestions.  Say "yes", and you're handing over your private moments—whether you shared them or not.Meta just launched a new AI superlab and is throwing around $10M pay packages to build it.  Zuckerberg's not just building chatbots—he's recruiting an AI dream team.Loadsa everything.  Let's go get rich!Find the full transcript to this podcast here.

In my opinion, Tucker Carlson's interview with RFK was a softball, limited hangout. Lot's of red meat for anti-vaxxers but no questions of true import.Here are a few of the questions I would have asked if I were to interview Secretary Kennedy:1. Why haven't you reversed the former HHS secretary's COVID-19 Public Health Emergency?2. Why haven't you used the bully pulpit to bring awareness and aid to the vaccine injured & dead?3. Why haven't you used the bully pulpit to publicly advocate for the PHARMA liability shields to be abolished?4. Why haven't you used your position as HHS secretary to withhold funding from states that enforce severe vaccine mandates for babies and children?5. Why haven't you pulled the mRNA shots OFF the market while you study them for safety?6. Why did you fast track SA-mRNA vaccines?7. Why is your agency still recommending COVID shots for immune compromised babies and pregnant mothers?8. Why hasn't your agency advised health practitioners to post ingredients lists, package inserts and potential adverse reactions for ALL vaccines to achieve true 'informed consent'?9. Why haven't you directed NIH director Jay Battacharya to launch a massive, nationwide study on vaccine related injuries and deaths?Is it any surprise RFK has never appeared on the SJ Show?Today we discuss this and more with special guest Seth Holehouse!Last week Ed Dowd warned of deep recession and recommended GOLD as the PREMIER safe haven, saying ‘gold is money good' … a Tier 1 asset.It is time to get your metals strategy in place! Call the company I trust, Colonial Metals Group today to learn about a gold strategy that works for you and see if you qualify for up to $7,500 in FREE silver! Check out my landing page here: https://colonialmetalsgroup.com/joyWe discuss this and MORE today on the SJ Show!Join the Rumble LIVE chat and follow my Rumble Page HERE so you never miss an episode: https://rumble.com/c/TheShannonJoyShowShannon's Top Headlines July 1, 2025:Ed Dowd Recommends GOLD: https://usawatchdog.com/gold-is-money-good-brace-for-deep-recession-ed-dowd/Trumps BBB Spells Fiscal Disaster: https://brownstone.org/articles/washingtons-fiscal-doomsday/BIS - Stablecoins FAIL As Money: https://www.technocracy.news/battle-line-drawn-bis-says-stablecoins-fail-as-money/Alex Jones Warns Of July 4 ‘Bioterror' Attack: https://x.com/newstart_2024/status/1939387250900619496SJ Show Notes:Please support Shannon's independent network with your donation HERE: https://www.paypal.com/donate/?hosted_button_id=MHSMPXEBSLVTSupport Our Sponsors:The Joy family is obsessed with Native Path Complete Protein!! It is the BEST way to get the protein your body needs EVERY day and it's on sale exclusively for the SJ audience!Go to https://nativepathcompleteprotein.com/joy today to claim your EXCLUSIVE 41% off deal before it's gone.With lockdowns looming, threats of bio-terror and cyber attacks, the chaos is everywhere. You NEED to be prepared and your one stop shop is The Satellite Phone Store. They have EVERYTHING you need when the POWER goes OUT. Use the promo code JOY for 10% off your entire order TODAY! www.SAT123.com/JoyPlease consider Dom Pullano of PCM & Associates! He has been Shannon's advisor for over a decade and would love to help you grow! Call his toll free number today: 1-800-536-1368 Or visit his website at https://www.pcmpullano.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

With  the appointment of Robert F Kennedy, Jr.  as Secretary of Health and Human Services, the Trump administration has systematically targeted the next generation of scientists and public health leaders. He has cut science funding to its lowest level in decades. More than 20,000 jobs were eliminated, billions of dollars in scientific research has been threatened or paused, and a budget draft proposes a major restructuring of Health and Human Services.The Trump administration has asked Federal agencies to cancel contracts with Harvard worth an additional $450 million after canceling more than $2.2 billion in federal research grants. Among these grants and contracts were medical research projects.The proposed budget for the NIH includes a 40% cut, the CDC faces a budget cut of about half its spending, and the NSF (National Science Foundation) 2026 budget would be cut in half. These budget cuts could  drastically affect the health of Americans for generations.RFK, Jr , fired 17 expert members of a committee that advises the CDC on what vaccines people in the United States should take and when, making families less safe.And RFK, Jr. aims to prohibit government scientists from publishing in top journals, citing pharmaceutical influence and corruption concerns. He proposes new in-house journals for NIH-funded research, questioning the peer-review process of established journals.To help us understand the ramifications of all of this, we invited Stephen Spielberg, MD to help us through the complexities of this strange time in medicine and science.I asked Steve for some background information so I could introduce him properly on this podcast.  He replied “if you wake me in the middle of the night and ask what I “do”, I would say I am a doctor, a pediatrician, and all I have done as a basic and clinical scientist, as a medical school dean, as deputy commissioner of the FDA – all that comes back to a focus on the care of sick children, the prevention of disease, and optimization of health, and remembering humbly that we are all human, all on a vast journey of learning and striving for a better world.”I urge you all to read Steve's full biography at our web site (https://www.specificallyforseniors.com) about this podcast.Steve and I discussed medical research in the time of the Trump administration, the arbitrary cuts in funding of the NIH FDA and CDC, vaccines, RFK's proposal that research documentation be submitted to a government controlled journal, the status of medical research and the United States standing in the international order, public health and funding cuts and his personal experience treating two brothers with a rare genetic disorder.MEMORY LANE INFORMATIONFor Individuals, Family and Caregivershttps://bit.ly/4mtTG2hThere is a 30% discount for annual subscriptions, please use code SFORSENIORS in the promo box.For Professional Care Facilitieshttps://www.memory-lane.tv/contact-adult-carePlease place "Specifically for Seniors" in the Ambassador LineResearchhttps://www.memory-lane.tv/researchDisclaimer: Specifically for Seniors receives a small stipend with each subscription that helps to keep the podcast on the air. Please use the links for further information

In a conversation recorded at the WBUR Festival, Dr. Anthony Fauci speaks frankly about the threats he sees to public health under the Trump administration and the “severe intimidation” of scientists at the NIH.

dr Nenad Tomašević gost je Vladimira Stankovića u 184. epizodi podkasta Biznis priče.

Abdul and Katelyn discuss a busy week in health news including: The most troubling aspects of this week's ACIP meeting, after RFK Jr's appointees convened to set vaccine policy for next fall. A flimsy deal among the nation's biggest health insurers, who mutually pinky-promised to improve their prior authorization processes. RFK Jr's announcement that the US will no longer fund GAVI, the global organization that vaccinates poor children around the world. A new court order that demands the Trump Administration reinstate hundreds of NIH grants. Then Abdul sits down with author and legal expert Leah Litman to discuss the biggest SCOTUS rulings of the year, and what it means for the future of public health. Check out our shop at store.americadissected.com for our new America Dissected merch – including logo shirts, hoodies and mugs. And don't miss our “Vaccines Matter. Science Works.” t-shirts! This show would not be possible without the generous support of our sponsors. America Dissected invites you to check them out. This episode was brought to you by: Boll & Branch: Feel the difference an extraordinary night's sleep can make. Get 15% off, plus free shipping on your first set of sheets at bollandbranch.com/ad

Since January, the National Institutes of Health (NIH) has made sweeping cuts to science. It's hard to keep track of how many research grants were canceled, but they add up to hundreds of millions—possibly billions—of dollars of research funding lost. Some scientists, like Dr. Katie Edwards, are taking the fight to the courts. Edwards studies interpersonal violence at the University of Michigan, and she speaks with Host Flora Lichtman about why she's suing the NIH.Guest: Dr. Katie Edwards is the director of the Interpersonal Violence Research Laboratory and a professor of social work at the University of Michigan. She studies violence against marginalized communities.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

A generation ago, a big clot in the brain meant paralysis or worse. Today, doctors can diagnose clots on AI-enabled brain scans; provide life-saving, targeted medications; or snake a catheter from a patient's groin into the brain to vacuum out the clot. If they intervene in time, they can watch speech and movement return before the sedatives wear off. How did that happen—and what's still missing?In this episode of From Our Neurons to Yours, Stanford neuroscientist and neurocritical care specialist Marion Buckwalter, MD, PhD retraces the 70-year chain of curiosity-driven research—biochemistry, imaging, materials science, AI—behind today's remarkable improvements in stroke care. She also warns what future breakthroughs are at stake if support for basic science stalls.Learn MoreBuckwalter Lab siteHistory of Stroke Care:Tissue Plasminogen Activator for Acute Ischemic Stroke (NINDS) On the development of the first-gen clot-busting drug, tPA Optimizing endovascular therapy for ischemic stroke (NINDS) On the development of mechanical clot clearance using thrombectomy.Mechanical Thrombectomy for Large Ischemic Stroke (Neurology, 2023) A literature meta-analysis shows that thrombectomy improves stroke outcomes by 2.5X, on top of 2X improvements from clot-busting drugsThe uncertain future of federal support for scienceThe Gutting of America's Medical Research: Here Is Every Canceled or Delayed N.I.H. Grant (New York Times, 2025)Trump Has Cut Science Funding to Its Lowest Level in Decades (New York Times, 2025)We want to hear from your neurons! Email us at at neuronspodcast@stanford.edu or... Send us a text!Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience. Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

In this episode of the Bill Press Pod, Bill discusses the alarming cuts to medical and scientific research imposed by the Trump administration. Over 1,300 NIH research grants and over 150 clinical trials, including those on critical diseases like HIV, cancer, and chronic diseases, have been canceled or delayed. Colette Delawalla, founder of Stand Up for Science, talks about the detrimental impact of these cuts on the U.S.'s global leadership in science and the brain drain of scientists to other countries. Additionally, data reporter Irena Hwang from The New York Times provides insight into the extent and reasons behind these cuts, revealing that keywords linked to DEI initiatives were a significant factor in the grant cancellations. The episode highlights the far-reaching consequences for public health and scientific progress. Gift Link to the New York Times article: bit.ly/44pTQk6Today Bill highlights the work of Collette Delawalla's Stand up for Science organization. More information at StandupforScience.net.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

You can text us here with any comments, questions, or thoughts!Looking for ways to diversify your research funding? Check out this week's episode where Kemi discuss how to get creative with non-NIH funding! Tailored especially for women of color in academic medicine and public health, Kemi shares her insights on the structural differences between NIH and other funding entities, emphasizing the need for adaptability in grant writing. Episode Highlights: Structural Differences between NIH vs. Other Funding Sources The Importance of Diversifying Your Funding Portfolio Writing for Non-NIH Applications: Key Strategies The Role of Theoretical Frameworks in Grant Writing Building Your Confidence and Passion for Your Work This episode is not just about securing grants; it's about reclaiming your narrative and empowering yourself to thrive in an evolving academic landscape. Tune in to gain insights that could transform your research career. If you'd like to learn more foundational career navigation concepts for women of color in academic medicine and public health, sign up for our KD Coaching Foundations Series: www.kemidoll.com/foundations.  REMINDER: Your Unapologetic Career Podcast now releases episode every other week! Can't wait that long? Be sure you are signed up for our newsletter (above) where there are NEW issues every month! 

The McCullough Report with Dr. Peter McCullough – January 2025 executive orders from the Trump administration halt certain high-risk gain-of-function studies at NIH to bolster biosecurity, and the Supreme Court's 6-3 decision upholds Tennessee's ban on gender-affirming care for minors, igniting debate over clinical protections and children's rights under emerging federal policies, including urgent public health implications...

The McCullough Report with Dr. Peter McCullough – January 2025 executive orders from the Trump administration halt certain high-risk gain-of-function studies at NIH to bolster biosecurity, and the Supreme Court's 6-3 decision upholds Tennessee's ban on gender-affirming care for minors, igniting debate over clinical protections and children's rights under emerging federal policies, including urgent public health implications...

Katherine Eban, Special Correspondent for Vanity Fair, and Dina Doll, well known legal analyst to the Meidas Mighty, join host Dr. Vin Gupta for an inside look within RFK Jr's HHS. Katherine discusses her most recent piece on the rise of Trump's top health advisor, Calley Means, while Dina discusses the real world impacts to American families of the cuts we're seeing across the FDA, CDC, and NIH.  Learn more about your ad choices. Visit megaphone.fm/adchoices

What do you get when you mix a surgeon, a scientist, and a self-proclaimed “tinkerer” who also happens to struggle with reflux? You get Dr. James Daniero—and you get this conversation about RefluxRaft. In this episode, Theresa Richard chats with Dr. Daniero, an ENT who's not just treating voice, airway, and swallowing disorders—he's innovating them. From basement experiments to biomaterials backed by NIH grants, Dr. Daniero walks us through how his personal journey with reflux turned into RefluxRaft, a barrier-based solution designed to help patients (and clinicians) think beyond PPIs. We dive into the science behind alginates, the "physics problem" behind reflux, and the collaborative power between ENTs, SLPs, and GIs. This one's for the med SLPs who want to understand the why behind the symptoms—and the potential tools to help. https://RefluxRaft.com Download show notes and references here: https://syppodcast.com/372 The post 372 – What If Reflux Isn't Just an Acid Problem? A New Way to Think About It with RefluxRaft appeared first on Swallow Your Pride Podcast.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Yolanda Ragland. A leading podiatric surgeon specializing in bunion and hammer toe correction. Here are some key highlights and themes from the conversation:

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Yolanda Ragland. A leading podiatric surgeon specializing in bunion and hammer toe correction. Here are some key highlights and themes from the conversation:

On the DSR Daily for Tuesday, we cover the latest from the Iran/Israel conflict, a federal judge ruling against some NIH grant cuts, the Department of Homeland Security restarting raids on farms, hotels, and restaurants, and more.  Learn more about your ad choices. Visit megaphone.fm/adchoices

USA TODAY White House Correspondent Francesca Chambers breaks down President Donald Trump's decision to abruptly leave the Group of Seven summit.Multiple lawmakers push to curb Trump's war powers on Iran.A federal prosecutor said Monday that the man accused of shooting two Minnesota lawmakers went to the homes of two other state officials the morning he launched a targeted "political assassination."USA TODAY Government Accountability Reporter Erin Mansfield discusses the trickle-down effect of Trump's NIH budget cuts.Trump Organization launches a new mobile cell service.Let us know what you think of this episode by sending an email to podcasts@usatoday.com.Episode Transcript available hereSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In October 2020, three contrarian medical professionals published The Great Barrington Declaration to great applause by the pro-business, anti-closure crowd. One of them, Jay Bhattacharya, now runs the NIH. Things are not going well under his watch. Last week, he was grilled in front of Congress about the $18B in proposed cuts to NIH funding. This happened a day after over 300 people under his guard published The Bethesda Declaration, a document filled with issues occurring under Bhattacharya's leadership. Derek discusses this new declaration and listens in on the Congressional hearing. The Bethesda Declaration An Uproar at the NIH The Disappearing Funds for Chronic Diseases Show Notes Learn more about your ad choices. Visit megaphone.fm/adchoices

Abdul and Katelyn discuss a rocky week in public health including: RFK Jr gutting ACIP to replace every member with his own appointees. The LA protests, and how immigration raids hurt community health Good trouble at NIH, as staff band together and demand director Jay Bhattacharya defend their research Then Abdul talks to Jaymes Black, CEO of The Trevor Project, about the Trump Administration's effort to weaponize the government against LBGTQ+ Americans, including cutting the 988 suicide Lifeline. We are off next week for the Juneteenth holiday. We will be back with another episode on June 26. Check out our shop at store.americadissected.com for our new America Dissected merch – including logo shirts, hoodies and mugs. And don't miss our “Vaccines Matter. Science Works.” t-shirts! This show would not be possible without the generous support of our sponsors. America Dissected invites you to check them out. This episode was brought to you by: de Beaumont Foundation: For 25 years, the de Beaumont Foundation has worked to create practical solutions that improve the health of communities across the country. To learn more, visit debeaumont.org.  Quince: Go to Quince.com/AD for free shipping on your order and 365-day returns.

Yes, things are dark. But if history has taught us anything, it's this: regimes fall, because people rise. Some soldiers will follow orders. Others won't. And that fault line? It's where dictatorships begin to crack. Just ask Romania in 1989, as we discussed in our March episode, “How to Overthrow a Dictator.” Meanwhile, Trump's team can't even staff the Pentagon, according to reports. No one who can put one foot in front of the other wants to work for “Whiskey Pete.”  The NIH is being gutted. Five-year research grants canceled in year four. Science is being purged, not for savings, but for submission. Stalin would be proud. So what do we do? We create. We resist. We document. We fund the arts. We fund scientists. We dance in the streets. Because protest is not just rage: it's dance, murals, color, joy. We outnumber them. They know it. That's why they're afraid. That's why they send in the troops. So unleash your inner rebel. Paint. Dance in the streets. Testify. We are all artists now. Want to enjoy Gaslit Nation ad-free? Join our community of listeners for bonus shows, ad-free episodes, exclusive Q&A sessions, our group chat, invites to live events like our Monday political salons at 4pm ET over Zoom, and more! Sign up at Patreon.com/Gaslit! EVENTS AT GASLIT NATION: NEW! We now have a Vermont Signal group for Gaslit Nation listeners in the state to find each other, available on Patreon. June 16 4pm ET – Gabe Garbowit and Keira Havens of Citizens' Impeachment join our salon to discuss the growing movement to impeach Donald Trump.  June 30 4pm ET – America has been here before. Book club discussion of Lillian Faderman's The Gay Revolution: The Story of the Struggle NEW! Arizona-based listeners launched a Signal group for others in the state to connect, available on Patreon. Indiana-based listeners launched a Signal group for others in the state to join, available on Patreon. Florida-based listeners are going strong meeting in person. Be sure to join their Signal group, available on Patreon. Have you taken Gaslit Nation's HyperNormalization Survey Yet? Gaslit Nation Salons take place Mondays 4pm ET over Zoom and the first ~40 minutes are recorded and shared on Patreon.com/Gaslit for our community Show Notes:  Trump's concentration camp bill: $160 billion to expand the powers of ICE and build a network of concentration camps https://www.wola.org/analysis/160-billion-to-detain-and-deport-congresss-reconciliation-bill-is-a-betrayal-of-priorities-and-will-harm-the-most-vulnerable/ CNN: Trump sends in the troops: https://bsky.app/profile/acyn.bsky.social/post/3lr76cgcuap26 Gavin Newsom & Federal Tax Boycott (Secession Hints) CBS News – What to Know About Newsom's Tax Threat https://www.cbsnews.com/news/california-gavin-newsom-federal-tax-boycott-trump-what-to-know/ Scientific Purges Bethesda Declaration – Defend NIH Scientists https://standupforscience.org/bethesda-declaration NIH scientists call on director to protect biomedical research https://www.npr.org/sections/shots-health-news/2025/06/09/nx-s1-5425466/nih-research-freedom-bethesda-declaration Resistance Art Show – KGNU, Boulder (7/11/25) https://kgnu.org/calendar ArtWorks for Milwaukee – Teen Art Internships (Donate) https://www.artworksformilwaukee.org/donate Zoe Leonard's Poem “I Want a Dyke for President” – Performed by Mykki Blanco https://www.youtube.com  “Invading Antifa Land” – The Stranger https://www.thestranger.com/news/2025/05/30/80080084/invading-antifa-land Protesters dancing in Los Angeles https://bsky.app/profile/cafastfoodunion.bsky.social/post/3lr7akcfywk2r  

The Trump Administration has decided that diversity, equity, and inclusion efforts are themselves a form of discrimination. And last week, the Supreme Court ruled unanimously that members of majority groups can also experience discrimination. But what if the entire frame of "discrimination" is the wrong one? Brando Simeo Starkey, author of "Their Accomplices Wore Robes: How the Supreme Court Chained Black America to the Bottom of a Racial Caste System" joins us to discuss how the Supreme Court has worked to ensure that Black Americans stay at the bottom of the racial hierarchy.And in headlines: California Governor Gavin Newsom sued the Trump administration over its deployment of the National Guard to Los Angeles, hundreds of NIH scientists issued a public letter condemning Trump's attacks on the agency, and Russia launched nearly 500 drones across Ukraine.Show Notes:Check out Brando Simeo Starkey's book – https://tinyurl.com/4chhn9c9Subscribe to the What A Day Newsletter – https://tinyurl.com/3kk4nyz8What A Day – YouTube – https://www.youtube.com/@whatadaypodcastFollow us on Instagram – https://www.instagram.com/crookedmedia/For a transcript of this episode, please visit crooked.com/whataday

Tuesday, June 10th, 2025Today, Pete Hegseth has mobilized the United States Marines against American citizens in Los Angeles County; Attorney General Bonta is suing the Trump administration seeking an injunction of National Guard deployment; ABC suspends Terry Moran for a tweet calling Stephen Miller a world class hater; a former Afghan soldier was arrested by ICE in Houston and stripped of his asylum protections; Pam Bondi's brother gets TROUNCED in the DC Bar Association election; Israeli forces detain Greta Thunberg after halting the Freedom Flotilla boat carrying aid and supplies; NIH employees publish the Bethesda declaration in dissent of Trump's cuts; RFK Jr ousts the entire CDC vaccination advisory committee; and Allison and Dana deliver your Good News.Thank You, CBDistilleryUse promo code DAILYBEANS at CBDistillery.com for 25% off your purchase.  Specific product availability depends on individual state regulations.Thank You, PacagenFor an extra 25% off your order and a special gift, head to Pacagen.com/DAILYBEANS.MSW Media, Blue Wave California Victory Fund | ActBlueMarines Unleashed In LA! Trump's Authoritarian Crackdown Intensifies with Allison GillCheck out Dana's social media campaign highlighting LGBTQ+ heroes every day during Pride Month -  Dana Goldberg (@dgcomedy.bsky.social) StoriesTrump administration activates 700 Marines in Los Angeles area amid ICE protests |CBS NewsFormer Afghan soldier arrested at Houston-area home by ICE, stripped of asylum protections, attorney says | Houston Public MediaGaza-bound aid boat with Greta Thunberg on board arrives in Israel after its seizure | AP NewsRFK Jr. ousts entire CDC vaccine advisory committee | AP NewsABC Suspends Terry Moran for Calling Stephen Miller a ‘World-Class Hater' | The New York TimesPam Bondi's brother overwhelmingly defeated in heated race to lead the D.C. Bar | NPR Good Trouble: - STAND UP FOR SCIENCE - On June 9th, 2025, federal employees at the National Institutes of Health (NIH) bravely stood up for the health and safety of the American people and faithful stewardship of public resources by authoring and signing the Bethesda Declaration. Sign the Open Letter in Support of NIH Public Servants - Action NetworkProton Mail: free email account with privacy and encryptionFind Upcoming Demonstrations And ActionsSat June 14 10am – 12pm PDT AG is hosting NO KINGS Waterfront Park, San DiegoDonation link - secure.actblue.com/donate/fuelthemovement250th Anniversary of the U.S. Army Grand Military Parade and Celebration50501 MovementJune 14th Nationwide Demonstrations - NoKings.orgIndivisible.orgFederal workers - feel free to email me at fedoath@pm.me and let me know what you're going to do, or just vent. I'm always here to listen. Check out other MSW Media podcastsShows - MSW Media, Cleanup On Aisle 45 podSubscribe for free to MuellerSheWrote on SubstackThe BreakdownFrom The Good NewsNational Portrait GalleryNobody Listens to Paula PoundstoneProtesters' Rights | American Civil Liberties UnionTAKE THE PLEDGE: Don't Rank Eric or Andrew for Mayor - Action Network Reminder - you can see the pod pics if you become a Patron. The good news pics are at the bottom of the show notes of each Patreon episode! That's just one of the perks of subscribing! patreon.com/muellershewrote Federal workers - feel free to email me at fedoath@pm.me and let me know what you're going to do, or just vent. I'm always here to listen.Share your Good News or Good TroubleMSW Good News and Good Trouble Check out other MSW Media podcastshttps://mswmedia.com/shows/Subscribe for free to MuellerSheWrote on Substackhttps://muellershewrote.substack.comFollow AG and Dana on Social MediaDr. Allison Gill Substack|Muellershewrote, BlueSky|@muellershewrote , Threads|@muellershewrote, TikTok|@muellershewrote, IG|muellershewrote, Twitter|@MuellerSheWrote,Dana GoldbergTwitter|@DGComedy, IG|dgcomedy, facebook|dgcomedy, IG|dgcomedy, danagoldberg.com, BlueSky|@dgcomedyHave some good news; a confession; or a correction to share?Good News & Confessions - The Daily Beanshttps://www.dailybeanspod.com/confessional/ Listener Survey:http://survey.podtrac.com/start-survey.aspx?pubid=BffJOlI7qQcF&ver=shortFollow the Podcast on Apple:The Daily Beans on Apple PodcastsWant to support the show and get it ad-free and early?Supercasthttps://dailybeans.supercast.com/Patreon https://patreon.com/thedailybeansOr subscribe on Apple Podcasts with our affiliate linkThe Daily Beans on Apple Podcasts

My guest is Dr. Jay Bhattacharya, MD, PhD, Director of the National Institutes of Health (NIH) and Professor Emeritus of Health Policy at Stanford University. We discuss which scientific questions ought to be the priority for NIH, how to incentivize bold, innovative science especially from younger labs, how to solve the replication crisis and restore trust and transparency in science and public health, including acknowledging prior failures by the NIH. We discuss the COVID-19 pandemic and the data and sociological factors that motivated lockdowns, masking and vaccine mandates. Dr. Bhattacharya shares his views on how to resolve the vaccine–autism debate and how best to find the causes and cures for autism and chronic diseases. The topics we cover impact everyone: male, female, young and old and, given that NIH is the premier research and public health organization in the world, extend to Americans and non-Americans alike. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman David: https://davidprotein.com/huberman Eight Sleep: https://eightsleep.com/huberman Levels: ⁠https://levels.link/huberman⁠ LMNT: https://drinklmnt.com/huberman Timestamps 00:00:00 Jay Bhattacharya 00:06:56 National Institutes of Health (NIH), Mission 00:09:12 Funding, Basic vs. Applied Research 00:18:22 Sponsors: David & Eight Sleep 00:21:20 Indirect Costs (IDC), Policies & Distribution 00:30:43 Taxpayer Funding, Journal Access, Public Transparency 00:38:14 Taxpayer Funding, Patents; Drug Costs in the USA vs Other Countries 00:48:50 Reducing Medication Prices; R&D, Improving Health 01:00:01 Sponsors: AG1 & Levels 01:02:55 Lowering IDC?, Endowments, Monetary Distribution, Scientific Groupthink 01:12:29 Grant Review Process, Innovation 01:21:43 R01s, Tenure, Early Career Scientists & Novel Ideas 01:31:46 Sociology of Grant Evaluation, Careerism in Science, Failures 01:39:08 “Sick Care” System, Health Needs 01:44:01 Sponsor: LMNT 01:45:33 Incentives in Science, H-Index, Replication Crisis 01:58:54 Scientists, Data Fraud, Changing Careers 02:03:59 NIH & Changing Incentive Structure, Replication, Pro-Social Behavior 02:15:26 Scientific Discovery, Careers & Changing Times, Journals & Publications 02:19:56 NIH Grants & Appeals, Under-represented Populations, DEI 02:28:58 Inductive vs Deductive Science; DEI & Grants; Young Scientists & NIH Funding 02:39:38 Grant Funding, Identity & Race; Shift in NIH Priorities 02:51:23 Public Trust & Science, COVID Pandemic, Lockdowns, Masks 03:04:41 Pandemic Mandates & Economic Inequality; Fear; Public Health & Free Speech 03:13:39 Masks, Harms, Public Health Messaging, Uniformity, Groupthink, Vaccines 03:22:48 Academic Ostracism, Public Health Messaging & Opposition 03:30:26 Culture of American Science, Discourse & Disagreement 03:36:03 Vaccines, COVID Vaccines, Benefits & Harms 03:47:05 Vaccine Mandates, Money, Public Health Messaging, Civil Liberties 03:54:52 COVID Vaccines, Long-Term Effects; Long COVID, Vaccine Injury, Flu Shots 04:06:47 Do Vaccines Cause Autism?; What Explains Rise in Autism 04:18:33 Autism & NIH; MAHA & Restructuring NIH? 04:25:47 Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, Sponsors, YouTube Feedback, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices